JP2006506327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006506327A5 JP2006506327A5 JP2004508111A JP2004508111A JP2006506327A5 JP 2006506327 A5 JP2006506327 A5 JP 2006506327A5 JP 2004508111 A JP2004508111 A JP 2004508111A JP 2004508111 A JP2004508111 A JP 2004508111A JP 2006506327 A5 JP2006506327 A5 JP 2006506327A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- receptor
- bip
- peptide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003042 antagnostic Effects 0.000 claims description 68
- 239000005557 antagonist Substances 0.000 claims description 66
- 230000000694 effects Effects 0.000 claims description 60
- 210000004027 cells Anatomy 0.000 claims description 28
- 102000005962 receptors Human genes 0.000 claims description 25
- 108020003175 receptors Proteins 0.000 claims description 25
- 230000000268 renotropic Effects 0.000 claims description 21
- 230000027455 binding Effects 0.000 claims description 19
- 238000004166 bioassay Methods 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 239000000816 peptidomimetic Substances 0.000 claims description 17
- 210000001519 tissues Anatomy 0.000 claims description 17
- 238000009739 binding Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 235000018102 proteins Nutrition 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 230000024924 glomerular filtration Effects 0.000 claims description 14
- 238000003786 synthesis reaction Methods 0.000 claims description 14
- 230000002194 synthesizing Effects 0.000 claims description 13
- 208000003278 Patent Ductus Arteriosus Diseases 0.000 claims description 11
- 239000000556 agonist Substances 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 206010038436 Renal failure acute Diseases 0.000 claims description 9
- 125000002252 acyl group Chemical group 0.000 claims description 8
- JCZLABDVDPYLRZ-AWEZNQCLSA-N Biphenylalanine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C1=CC=CC=C1 JCZLABDVDPYLRZ-AWEZNQCLSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 230000001976 improved Effects 0.000 claims description 7
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 208000009863 Chronic Kidney Failure Diseases 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 150000008575 L-amino acids Chemical class 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 5
- 230000036151 Urine output Effects 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 5
- IVOMOUWHDPKRLL-KQYNXXCUSA-N cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims description 4
- 230000024245 cell differentiation Effects 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 201000000523 end stage renal failure Diseases 0.000 claims description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 230000001413 cellular Effects 0.000 claims description 3
- 230000002209 hydrophobic Effects 0.000 claims description 3
- 230000016160 smooth muscle contraction Effects 0.000 claims description 3
- 150000008574 D-amino acids Chemical class 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 3
- 229960002685 biotin Drugs 0.000 claims 3
- 235000020958 biotin Nutrition 0.000 claims 3
- 239000011616 biotin Substances 0.000 claims 3
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims 2
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims 2
- 125000003290 L-leucino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims 2
- 210000004748 cultured cells Anatomy 0.000 claims 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 claims 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 claims 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 101710011551 PTGER4 Proteins 0.000 description 109
- 102100017607 PTGER4 Human genes 0.000 description 97
- 235000001014 amino acid Nutrition 0.000 description 48
- 150000001413 amino acids Chemical class 0.000 description 44
- 241000700159 Rattus Species 0.000 description 38
- 150000001875 compounds Chemical class 0.000 description 31
- 108090000765 processed proteins & peptides Proteins 0.000 description 28
- 102000004196 processed proteins & peptides Human genes 0.000 description 28
- XEYBRNLFEZDVAW-ARSRFYASSA-N (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 25
- 229960002986 dinoprostone Drugs 0.000 description 25
- 230000003907 kidney function Effects 0.000 description 21
- 210000002700 Urine Anatomy 0.000 description 16
- 239000003814 drug Substances 0.000 description 14
- 210000003734 Kidney Anatomy 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 210000004369 Blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 229940079593 drugs Drugs 0.000 description 11
- 230000001965 increased Effects 0.000 description 11
- -1 lle Chemical compound 0.000 description 11
- 150000003180 prostaglandins Chemical class 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 206010069384 Ischaemic nephropathy Diseases 0.000 description 9
- 210000002254 Renal Artery Anatomy 0.000 description 9
- 206010038435 Renal failure Diseases 0.000 description 9
- 201000006370 kidney failure Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000002966 Serum Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229960004316 cisplatin Drugs 0.000 description 8
- 230000000875 corresponding Effects 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 8
- 230000036325 urinary excretion Effects 0.000 description 8
- 229940109239 Creatinine Drugs 0.000 description 7
- TVURRHSHRRELCG-UHFFFAOYSA-N Fenoldopam Chemical compound C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 description 7
- 210000003752 Saphenous Vein Anatomy 0.000 description 7
- 235000004279 alanine Nutrition 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000000051 modifying Effects 0.000 description 7
- 230000002829 reduced Effects 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 210000004072 Lung Anatomy 0.000 description 6
- 210000002997 Osteoclasts Anatomy 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 210000002381 Plasma Anatomy 0.000 description 6
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 6
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 6
- 102000017953 Prostanoid receptors Human genes 0.000 description 6
- 108050007059 Prostanoid receptors Proteins 0.000 description 6
- 230000001154 acute Effects 0.000 description 6
- 230000004059 degradation Effects 0.000 description 6
- 229960002724 fenoldopam Drugs 0.000 description 6
- 230000000670 limiting Effects 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000006011 modification reaction Methods 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000002148 osteoclast Effects 0.000 description 6
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 5
- 210000003754 Fetus Anatomy 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 206010038540 Renal tubular necrosis Diseases 0.000 description 5
- 230000036687 URINARY FLOW RATE Effects 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000000423 cell based assay Methods 0.000 description 5
- 230000002354 daily Effects 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001605 fetal Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LQANGKSBLPMBTJ-BRSNVKEHSA-N (Z)-7-[(1S,2S,3R,4R)-3-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid Chemical compound C1[C@@H]2CO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O LQANGKSBLPMBTJ-BRSNVKEHSA-N 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 208000001083 Kidney Disease Diseases 0.000 description 4
- HSMNQINEKMPTIC-UHFFFAOYSA-N N-(4-aminobenzoyl)glycine Chemical compound NC1=CC=C(C(=O)NCC(O)=O)C=C1 HSMNQINEKMPTIC-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 102000008866 Prostaglandin E Receptors Human genes 0.000 description 4
- 108010088540 Prostaglandin E Receptors Proteins 0.000 description 4
- 206010048988 Renal artery occlusion Diseases 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000002146 bilateral Effects 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 231100000673 doseâresponse relationship Toxicity 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001603 reducing Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 210000000988 Bone and Bones Anatomy 0.000 description 3
- 102000003688 G-protein coupled receptors Human genes 0.000 description 3
- 108090000045 G-protein coupled receptors Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 206010029151 Nephropathy Diseases 0.000 description 3
- 108091005771 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 210000001147 Pulmonary Artery Anatomy 0.000 description 3
- 102100000775 REN Human genes 0.000 description 3
- 206010061481 Renal injury Diseases 0.000 description 3
- 108090000783 Renin Proteins 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 3
- 108090001123 antibodies Proteins 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 210000001100 crypt cell Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 102000037240 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000302 ischemic Effects 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000003278 mimic Effects 0.000 description 3
- 108091005593 modified peptides Proteins 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000004936 stimulating Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000002485 urinary Effects 0.000 description 3
- FRLGFEJDRMTGHL-YFKPBYRVSA-N (2S)-6-amino-2-(carboxyamino)hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(O)=O FRLGFEJDRMTGHL-YFKPBYRVSA-N 0.000 description 2
- 241000269328 Amphibia Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 210000001715 Carotid Arteries Anatomy 0.000 description 2
- VXIVSQZSERGHQP-UHFFFAOYSA-N Chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 2
- 210000001072 Colon Anatomy 0.000 description 2
- 241000565118 Cordylophora caspia Species 0.000 description 2
- 102000019460 EC 4.6.1.1 Human genes 0.000 description 2
- 108060000200 EC 4.6.1.1 Proteins 0.000 description 2
- 210000003743 Erythrocytes Anatomy 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 229960000905 Indomethacin Drugs 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 210000000936 Intestines Anatomy 0.000 description 2
- 206010061255 Ischaemia Diseases 0.000 description 2
- 210000004731 Jugular Veins Anatomy 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 206010029149 Nephropathy Diseases 0.000 description 2
- 101710040930 PTGS2 Proteins 0.000 description 2
- 102100015381 PTGS2 Human genes 0.000 description 2
- 102000035443 Peptidases Human genes 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 206010061529 Polyp Diseases 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 210000001525 Retina Anatomy 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000015076 Shorea robusta Nutrition 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229960004567 aminohippuric acid Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- DGAKHGXRMXWHBX-UHFFFAOYSA-N azoxymethane Chemical compound CN=[N+](C)[O-] DGAKHGXRMXWHBX-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 101710027542 codAch2 Proteins 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal Effects 0.000 description 2
- 200000000010 kidney injury Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000000414 obstructive Effects 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000000790 osteoblast Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 229920001690 polydopamine Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002441 reversible Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-M thromboxane A2(1-) Chemical compound [O-]C(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-M 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2S)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- HKUAWRVNDCVEHT-NSHDSACASA-N (2S)-2-(pyren-4-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC3=CC=CC4=CC=C1C2=C34 HKUAWRVNDCVEHT-NSHDSACASA-N 0.000 description 1
- VOIZSAUUYAGTMS-LURJTMIESA-N (2S)-2-amino-3-thiophen-3-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC=1C=CSC=1 VOIZSAUUYAGTMS-LURJTMIESA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- INAPMGSXUVUWAF-XCMZKKERSA-N 1D-myo-inositol 6-phosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-XCMZKKERSA-N 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-Trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-YNNPMVKQSA-N 9α,11α-PGF2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 description 1
- YRKCREAYFQTBPV-UHFFFAOYSA-N Acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
- 229960004373 Acetylcholine Drugs 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 210000000709 Aorta Anatomy 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- WTOFYLAWDLQMBZ-LURJTMIESA-N Beta(2-Thienyl)Alanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CS1 WTOFYLAWDLQMBZ-LURJTMIESA-N 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 229960005309 Estradiol Drugs 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N Ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Farmotal Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 229960000304 Folic Acid Drugs 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007522 Fused Kidney Diseases 0.000 description 1
- 108091006011 G proteins Proteins 0.000 description 1
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 102100020039 HPGDS Human genes 0.000 description 1
- 101700056286 HPGDS Proteins 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N Halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 Halothane Drugs 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 210000001308 Heart Ventricles Anatomy 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 210000002011 Intestinal Secretions Anatomy 0.000 description 1
- 206010048616 Intestinal polyp Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid zwitterion Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical class OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical class CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-α-phenylglycine Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 102100015262 MYC Human genes 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 210000000754 Myometrium Anatomy 0.000 description 1
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 210000000885 Nephrons Anatomy 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 231100000637 Nephrotoxin Toxicity 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N Nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N Ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 210000002826 Placenta Anatomy 0.000 description 1
- 230000036823 Plasma Levels Effects 0.000 description 1
- 230000037289 Plasma half life Effects 0.000 description 1
- 230000037240 Plasma half-life Effects 0.000 description 1
- 230000036660 Plasma protein binding Effects 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N Prostacyclin Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N Prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 229960003581 Pyridoxal Drugs 0.000 description 1
- 229960001327 Pyridoxal Phosphate Drugs 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038428 Renal disease Diseases 0.000 description 1
- 206010038444 Renal failure chronic Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N Roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 206010039911 Seizure Diseases 0.000 description 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N Succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
- 241000278713 Theora Species 0.000 description 1
- 229960003279 Thiopental Drugs 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N Thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 210000001541 Thymus Gland Anatomy 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical class [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 210000000626 Ureter Anatomy 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 230000036659 Urine excretion Effects 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 229940046008 Vitamin D Drugs 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 210000002268 Wool Anatomy 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N Xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 Xylazine Drugs 0.000 description 1
- GUBXYMKIJFOYOA-YMGPVYFXSA-N [(2R)-2-formyloxy-3-[hydroxy-[(2R,3S,5R,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] formate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(=O)OC[C@@H](COC=O)OC=O)[C@H](O)[C@@H]1O GUBXYMKIJFOYOA-YMGPVYFXSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 102000000072 beta-Arrestins Human genes 0.000 description 1
- 108010080367 beta-Arrestins Proteins 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 238000004638 bioanalytical method Methods 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- SJOVRJIZOJKXLQ-UHFFFAOYSA-N chloroboranuide Chemical compound Cl[BH3-] SJOVRJIZOJKXLQ-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 230000003205 diastolic Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000002121 endocytic Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-M glyoxylate Chemical compound [O-]C(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-M 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000034443 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006077 heterotrimeric G proteins Proteins 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 125000003372 histidine group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000640 hydroxylating Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001969 hypertrophic Effects 0.000 description 1
- 150000002463 imido esters Chemical class 0.000 description 1
- 230000000984 immunochemical Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 200000000001 labour Diseases 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- NEGQCMNHXHSFGU-UHFFFAOYSA-N methyl pyridine-2-carboximidate Chemical compound COC(=N)C1=CC=CC=N1 NEGQCMNHXHSFGU-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical class [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 101710005265 pgdP Proteins 0.000 description 1
- 101710027185 pgiA1 Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003166 prostaglandin E2 derivatives Chemical class 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000013878 renal filtration Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000000261 vasodilator Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- OJUGVDODNPJEEC-UHFFFAOYSA-N α-oxobenzeneacetaldehyde Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 1
Description
çºæã®åé
æ¬çºæã¯ãããã¹ã¿ã°ã©ã³ãžã³EP2ã®å容äœãµãã¿ã€ãEP4ã®ã¢ã³ã¿ãŽãã¹ãã»ããªããããã«é¢ãããããå ·äœçã«æ¬çºæã¯ãããã¹ã¿ã°ã©ã³ãžã³E2ã®å容äœãµãã¿ã€ãEP4ã®ããªããããã»ã¢ã³ã¿ãŽãã¹ãã«é¢ãããããŠæžå°¿æ§è çã骚åžåãè žå ã¯ãªãã(crypt)现èã®ç°åžžãªå¢æ®åã¯åè管éåçãšé¢é£ããçŸæ£ã®å»è¬ççç¶ã®æ²»çã«ããããã䜿çšããããšã«é¢ããã
æ¬çºæã¯ãããã¹ã¿ã°ã©ã³ãžã³EP2ã®å容äœãµãã¿ã€ãEP4ã®ã¢ã³ã¿ãŽãã¹ãã»ããªããããã«é¢ãããããå ·äœçã«æ¬çºæã¯ãããã¹ã¿ã°ã©ã³ãžã³E2ã®å容äœãµãã¿ã€ãEP4ã®ããªããããã»ã¢ã³ã¿ãŽãã¹ãã«é¢ãããããŠæžå°¿æ§è çã骚åžåãè žå ã¯ãªãã(crypt)现èã®ç°åžžãªå¢æ®åã¯åè管éåçãšé¢é£ããçŸæ£ã®å»è¬ççç¶ã®æ²»çã«ããããã䜿çšããããšã«é¢ããã
ããã¹ã¿ã°ã©ã³ãžã³ã¯ãããã¹ã¿ã°ã©ã³ãžã³(PG)ã·ã³ã¿ãŒãŒã«ããã¢ã©ã®ãã³é
žã®é
žçŽ ä»å ããèªå°ããããããã¹ã¿ã°ã©ã³ãžã³ã¯ãè¡ç®¡ã®éåæ§ãç¡ç /èŠéã®ãµã€ã¯ã«ãè
žå
ã®åæ³ãèèªã®å解ã糞çäœã§ã®æ¿Ÿéããã¹ã现èã®é¡ç²æžå°ãç¥çµäŒéãè¡å°æ¿åéåãçœè¡çã®ç Žå£ãåå®®çåçž®åã³ååš©(myometrial contraction and labor)ãççåã³é¢ç¯çãåè管éåçã现èã®å¢æ®åã³ååãªã©ã®çš®ã
ã®ççäœçšãä»åšãããããã¹ã¿ãã€ãããïŒåã®è貫éããªã«ã«å容äœã®ãããã·ã³æ§ã¹ãŒããã¡ããªãŒã«å±ããæããã«å€å¥ã§ããå容äœãžã®çµåãä»ããããã®æŽ»æ§ãä»åšããããããã®å容äœããαãβåã³Î³ã®ãµããŠãããããæ§æãããç°çš®3éäœã®G-ã¿ã³ãã¯è³ªã«çµåããããã®G-ã¿ã³ãã¯è³ªãã掻æ§ã«åºã¥ããŠçŽ°èäžã®ã«ã«ã·ãŠã ã®å€åããã¹ãã€ãã·ããã®å æ°Žå解åã¯ç°ç¶ã¢ããã·ã³1ãªã³é
žåæã®ä¿é²åã¯é»å®³(Narumiya,S.ãã1999;Physiol.Rev.79:1193-1226ãåç
§)ã®éå§ãæ¹èµ·ããã
è¬ççã«æãããªïŒçš®ã®ããã¹ã¿ãã€ãå容äœãPGE2,PGI2,PGD2,PGF2α,åã³TxA2ã®ãã¡ãPGE2å容äœã®4ã®ãµãã¿ã€ããèšèŒãããŠãã(Ichikawaãã1996)ããããã¯ã幟ã€ãã®ã¹ãã©ã€ã¹ã»ããªã¢ã³ããæããEP1,EP2,EP3ããšãããŠEP4ã§ãããã¯ããŒã³åããããã®EP4(åã¯ããã¹ã¿ã°ã©ã³ãžã³E2ã®å容äœãµãã¿ã€ãEP4ãšããŠåšç¥)ãã488ã®ã¢ããé
žã®ç³ã¿ã³ãã¯è³ªã§ãããGαsã«çµåããããããŠã¢ããã«é
žã·ã¯ã©ãŒãŒåã³cAMPåæã®åºæ¿ã«é¢äžãã(ç±³åœç¹èš±çªå·5,759,789åã³5,605,814)ã
EP4å容äœããè
žå
ã§é«ã¬ãã«ã«çºçŸãããããèºãè
èãèžè
ºãåå®®åã³è³å
ã§ææã«äœãã¬ãã«ã«ãŠçºçŸããã(Bastien,Y.ãã1994;J.Biol.Chem.269(16):11873-77ãåç
§)ãEP4å容äœããè
èå
ã®æµåç©ã®æ¿Ÿéãåç/ãã¯ããã¡ãŒãžåé§äœã®ç ŽéªšçŽ°èãžã®ååãè
žå
ã¯ãªãã(crypt)现èã®å¢æ®ãåã³åºä¹³åç©èå
ã®åè管éåçã«é¢äžããŠããã
PGE2ã¯ãè
èå
ã§è±å¯ã«ç£çããããããŠè
ã«ããã埮å°åŸªç°ãå¡©åã³æ°Žã®èŒžéãåã³ã¬ãã³(renin)ã®æŸåº(Breyer,M.D.ãã1998;Kidney Int.54(Suppl.67):S88-94ãåç
§)ã®èª¿ç¯ã«é¢äžããŠãããå
šãŠã®EPå容äœããè
æ§é äœã®å±éšã«åæ£ãã(Morath,Rãã1999;J.Am.Soc.Nephrol.10:1851-60ãåç
§)ããããŠç¹å®æ©èœãšé¢ä¿ä»ããããŠãããè
èå
ã®EPå容äœã®ååžã«é¢ãè¡ãªãããããããç 究ã§ç€ºãããããšã¯ãEP4å容äœãã糞çäœå
ã§ç¬ç¹ã®çºçŸããã(Breyer,M.D.ãã1996;Am.J.Physiol.270:F912-918.Morath,Rãã1999;J.Am.Soc.Nephrol.10:1851-60ãåç
§)ãããããªãããéå管(collecting duct)(Breyer,M.Dãã1998;Kidney Int.54(Suppl.67):S88-94)ãè
åèåã³çŽç®¡(vasa recta)ã®åªäœ(Morath,R.ãã1999;J.Am.Soc.Nephrol.10:1851-60)ãªã©ãããã³ã®ä»ã®æ§é äœã«ãããå容äœã®ååšããå¥ã
ã«èšèŒãããŠãããããã«EP4ã®è»¢åããè¿æ¥ãã糞çäœã®é¡ç²çŽ°èã«èŠåºããããããŠãããã®çŽ°èå
ã§PGE2ã«ãŠèªå°ãããcAMPã®åæãšäžèŽãããåŸã£ãŠEP4ããã¬ãã³(renin)åæ³ã®åœ¹å²ãæããããšãã§ããã
糞çäœã®ããã¹ã¿ã°ã©ã³ãžã³ããæ¿Ÿé(Schlondoff,D.ãã1987;Kidney Int.29:108-19)åã³ã¬ãã³æŸåºã«åœ±é¿ãäžãããšèãããããPGE2ããåé¢ããã糞çäœäžã§cAMPã®ã¬ãã«ãå¢å€§ããã(Freidlander,G.ãã1983;Mol.Cell.Endocrinol.30:201-214ãåç
§)ãããã¯ãcAMPåæäœã«çµåããEP4å容äœãã糞çäœã«ããæ¿Ÿéã調ç¯ã§ãã(Sugimoto,Y.ãã1994;Am.J.Physiol.266(5 Pt 2):F823-8)ããšã瀺åãããå°ååã¢ã³ã¿ãŽãã¹ã(Kohno,YããWO 00/16760)ãåã³ããããã»ã¢ã³ã¿ãŽãã¹ã(Peri,K.G.ããWO 00/16760)ã䜿çšããããšã§ãè
èã«ããæ¿Ÿéåã³å°¿æåºã調ç¯ããEP4ã®çŽæ¥ç圹å²ãå®èšŒãããã
骚ãé£ç¶çã«åæ§ç¯ãåããããã§éªšåœ¢æã骚èœçŽ°èã«ãã£ãŠè¡ãªããã骚åžåãç ŽéªšçŽ°èã«ãã£ãŠè¡ãããããããã®éçšã¯ããã©ããªã€ãã»ãã«ã¢ã³ããšã¹ãã©ãžãªãŒã«ããã¿ãã³Dããµã€ãã«ã€ã³ãå¢æ®å ååã³ããã¹ã¿ã°ã©ã³ãžã³ãªã©ã®å¹Ÿã€ãã®ãã«ã¢ã³å åã«ããå¶åŸ¡ãããŠãããã€ã³ã¿ãŒãã€ãã³-1(IL-1)ã«ããç Žéªšãžã®èªçºããã¢ã¹ããªã³æ§è¬å€ã«ãã£ãŠé»å®³ããã(Tai,Hã1997)ããšã瀺ããããEP4å容äœã®ã¢ãŽãã¹ã掻æ§ãæããPGE2ã®é¡äŒŒäœ(ãã®å容äœã«å¯Ÿãéç¹ç°çã¢ãŽãã¹ãåã¯ã¢ã³ã¿ãŽãã¹ãããããŸã§ã«ååšãã)ããããŠã¹ã®éªšèœçŽ°èãšéªšé«çŽ°èãšã®å
±å¹é€ã«ãããç ŽéªšçŽ°èã®åœ¢æãä¿é²ãããEP4ããã¯ã¢ãŠãã»ããŠã¹ããã®çŽ°èãçšããåæ§ã®å®éšã§ã¯ãç ŽéªšçŽ°èã®åœ¢æã®æžå°ãçãããã®ããšãããŠã¹ã®ç Žéªšåœ¢æã«ãããEP4å容äœã®åœ¹å²ã瀺åããŠãã(Narumiyaãã1999)ã
åè管ããäžè¬ã«å€§ãããŠæµææ§ãäœããèå
ã«ãããã·ã£ãŠã³ãè¡ç®¡ã§ãèºãžã®è¡ç®¡ãã€ãã¹ã容æã«ãããèå
ã¯ãèªåã®èºã䜿çšããŠããªã(é
žçŽ ãæ¯äœã®èç€ããæäŸããã)ãããèå
ã®èºãæãç³ãŸããç¶æ
ã§è¡æµã«é«ãæµææ§ãåã£ãŠãããåŸã£ãŠè¡æ¶²ããå³å¿å®€ãã管ãéãéäžããŠãã倧åèãžãšæµããŠãããããã¹ã¿ã°ã©ã³ãžã³ãç¹ã«PGE2ãé«ã¬ãã«ã«åŸªç°ããããšã§ãèã®éå£éš(foot open)ã®ç®¡(ductus)ãç¶æããããèå
ãçãŸããšèºãèšåŒµããèºåèã®æµææ§ãäœäžãããPGE2ã®ã¬ãã«ãæžå°ãã管(ductus)ã®ééãå§ãŸããç¶ããŠè¡æ¶²ãèºåèããèºãžæµå
¥ããããæ°çå
ã«ãããŠé«ã¬ãã«ã®é
žçŽ ã«ããããã®ç®¡ããã°ãã°ééãããã»ãšãã©ã®å Žå24æé以å
ã«ãã®ç®¡ãééããããåè管éåç(PDA)ã¯ã管ãééããªãçç¶ã§ãããPDAã®å Žåã®çœ¹ç
çãšæ»äº¡çããåè管ãéãæµéãšçŽæ¥çã«é¢é£ããŠãããé節ãªPDAããèºåèã«ããé«è¡å§ãæµ®è
«ãåçºæ§ææãèµ·ãããããã«é·æéæ²»çããæŸçœ®ãããšå¿èæ©èœé害ãèµ·ãããèºè¡ç®¡ã®éå¡çŸæ£ãçºçããå¯èœæ§ããããæ²»çããã«æŸçœ®ãããšæ»äº¡çãã20æ³ã§20%ã45æ³ã§42%ããããŠ60æ³ã«ãŠ60%ã§ãããšäºæž¬ãããã女æ§ã§ã¯æããPDAã®çºçããç·æ§ãã2ä¹è³3åå€ãã
PDAããããã¹ã¿ã°ã©ã³ãžã³åæã®åæ¢å€ã§ããã€ã³ãã¡ã¿ã·ã³(Indomethacin)ãªã©ã®è¬å€ããå€ç§çç¯æ£ãã®ããããã§æ²»çå¯èœã§ãããããããªãããã€ã³ãã¡ã¿ã·ã³(Indomethacin)ããè
èè¡åã³è
èã®èå(hypofusion)çæ§ãžã®å¯äœçšãæãããã®çµææ©ç£ã«ããèå
ã«ãããŠèæ¬ æ§è
çŸæ£ãèµ·ããããšã«ãªããEP4ããèå
ãã¿(Bhattacharya,Mãã1999;Circulation 100(16):1751-6)ãèå
ã€ã®(Bouayad,Aãã2001;Am.J.Physiol.Heart Cir.c Physiol.280(5);H2342-9)åã³èå
ãã(Smith G.C.ãã2001;J.Cardiovasc.Pharmacol.37(6):697-704)ã®åè管ã«ãŠçºçŸããããéã«èšããšEP4ã®ããã¯ã¢ãŠãã»ããŠã¹ããåºçåŸäžååãªåè管ééã«ããæ»ã«è³ã(Nguyen,Mãã1997;Nature,390:78-81ãåç
§)ã
EP4å容äœã®éžæçããããã»ã¢ã³ã¿ãŽãã¹ãããèå
ã®åè管ã®æ²»çã«äœ¿çšããã(Peri,K.G.ããWO 01/42281 and Wright,D.H.ããAm.J Physiol.Regul.Integr.Comp.Physiol.2001;281(5):R1345-60ãåç
§)ã
ããã¹ã¿ã°ã©ã³ãžã³ã®ãã¡ç¹ã«PGE2ããè
žå
ã®ã¯ãªãã(crypt)现èã®å¢æ®ã«éèŠãªåœ¹å²ãæããŠãããå®éã«èªçºæ§ããã¹ã¿ã°ã©ã³ãžã³åæé
µçŽ ã§ããCOX-2ã¯ãè
žå
ã®ããªãŒãåã³çµè
žã®è
«çäžã«ååšããããšã瀺ããã(Shattuck-Brandt,R.L.ãã1999;Mol.Carinog.24(3):177-87ãåç
§)ããã¡ã¹ã©ã€ã(Nimesulide)ãªã©ã®COX-2ãžã®éžæçåæ¢å€(blockers)ããçµè
žã¬ã³çºçã®ååŠçèªçºã®é»å®³ã«äœ¿çšããã(Jacoby,R.F.ãã2000;Cancer Res.60(18):5040-4ãåç
§)ãè¿å¹ŽPGE2ã®æŽ»æ§ã¯ãEP4-/-ããŠã¹ã®çµè
žããªãŒãã®çºççãäœãããšããæšå®ããŠEP4å容äœã®ä»åšã瀺ããããã®èŠå ãšããŠã¯ãã¢ãŸãã·ã¡ã¿ã³ã«ããããããŠã¢ãŸãã·ã¡ã¿ã³ã«ãŠåŠçãããããã»ããŠã¹(min mice)ã«ãããŠç°åžžã¯ãªãã(crypt)ç
å·£ã®æžå°ã«EP4ãžã®éžæçã¢ã³ã¿ãŽãã¹ããONO-AE2-227(Mutoh,M.ã2002;Cancer Res.62(1):28-32)ã®å¹æã«èµ·å ããŠããã
åŸã£ãŠããã¹ã¿ã°ã©ã³ãžã³E2ã®å容äœãµãã¿ã€ãEP4ã®éžæçããªããããã»ã¢ã³ã¿ãŽãã¹ããçæãããå¿
èŠãããããã®ããšããçµè
žã¬ã³ã®çºçãæ²»çããããŠé»å®³ããã«æçã§ããã
ããã«ãæ°çå
ã«ãããåè管éå(PDA)çã®ç®¡ééãé»å®³ããçç¶ã«å ããæ«æã®è
çŸæ£ãæ¥æ§è
äžå
šãåã³éªšç²é¬çã«ããã骚åžåãé»å®³ããè
äžè¯(insufficiency)ã«ããä»ã®çç¶ã®æ²»çæ¹æ³ãå¿
èŠã§ããã
ããã«çŸæ£éçšã®äž»èŠéšåã§ãã骚ç²é¬çãæ¯ã®çŸæ£ãåã³ä»ã®çŸæ£ãªã©ã®å»è¬ççç¶ã®æ²»çæ¹æ³ãå¿
èŠã§ããã
æ¬çºæãæ±ããããšã¯ããããã®èŠæåã³ä»ã®èŠæãæºãããšã§ããã
æ¬èšèŒãå€ãã®æç®ã«èšåããããããã®å
容ã¯ãæ¬æ现æžã«ãã®å
šäœãåŒçšã«ããçµã¿å
¥ããããŠããã
çºæã®èŠçŽ
ããã¹ã¿ã°ã©ã³ãžã³E2ã®å容äœãµãã¿ã€ãEP4ã®éžæçããããã»ã¢ã³ã¿ãŽãã¹ããèšèŒããããããã®ããããã»ã¢ã³ã¿ãŽãã¹ãããæ¥æ§åã³é²è¡æ§è èçŸæ£ã骚ç²é¬çãæ¯ã®çŸæ£ãåã³åè管éåçãšèšºæãããæ£è ãåã¯ããããçŸæ£ãçºçããå±éºæ§ã®ããæ£è ãæ²»çããå»è¬çµæç©ãçæããããã«äœ¿çšããããšãã§ããã
ããã¹ã¿ã°ã©ã³ãžã³E2ã®å容äœãµãã¿ã€ãEP4ã®éžæçããããã»ã¢ã³ã¿ãŽãã¹ããèšèŒããããããã®ããããã»ã¢ã³ã¿ãŽãã¹ãããæ¥æ§åã³é²è¡æ§è èçŸæ£ã骚ç²é¬çãæ¯ã®çŸæ£ãåã³åè管éåçãšèšºæãããæ£è ãåã¯ããããçŸæ£ãçºçããå±éºæ§ã®ããæ£è ãæ²»çããå»è¬çµæç©ãçæããããã«äœ¿çšããããšãã§ããã
æ¬çºæã¯ãå容äœæŽ»æ§ã®å°ãªããšã1ã®æ©èœççµæãé»å®³ã§ãããããã¹ã¿ã°ã©ã³ãžã³E2ã®å容äœãµãã¿ã€ãEP4ã¢ã³ã¿ãŽãã¹ãã®éžæçãªãããã圢ç¶ãåã¯ããããæš¡å£ç©ã®åœ¢ç¶ã«é¢ããã
æ¬çºæã¯ãããã¹ã¿ã°ã©ã³ãžã³E2ã®å容äœãµãã¿ã€ãEP4ã®éžæçãªããããã»ã¢ã³ã¿ãŽãã¹ãã«é¢ããã
ããã«æ¬çºæã¯ãçµè
žã¬ã³çºçã®æ²»çåã³é²æ¢ã«æçãªãããã¹ã¿ã°ã©ã³ãžã³E2ã®å容äœãµãã¿ã€ãEP4ã®éžæçããããã»ã¢ã³ã¿ãŽãã¹ãã«é¢ããã
ããã«æ¬çºæã¯ãæ«æã®è
èçŸæ£ãæ¥æ§è
äžå
šãåã³éªšç²é¬çã®éªšåžåãé»å®³ããè
æ©èœäžè¯(insufficiency)ã®ä»ã®çç¶ã䞊ã³ã«æ°çå
ã®åèšç®¡(PDA)ééãé»å®³ããçç¶ã®æ²»çã«ãããŠæå¹ãªããã¹ã¿ã°ã©ã³ãžã³E2ã®å容äœãµãã¿ã€ãEP4ã«ãããéžæçããããã®ãåã¯ããããæš¡å£ç©ã®ã¢ã³ã¿ãŽãã¹ããå«ãã§æãå»è¬çµæç©ã«é¢ããã
ããã«æ¬çºæã¯ã骚ç²é¬çãæ¯ã®çŸæ£ããããŠéªšæå·ãçŸæ£éçšã®äž»èŠéšåãæ§æããä»ã®çŸæ£ãªã©ã®å»è¬çç¶ã®æ²»çã«æå¹ãªéžæçEP4ã¢ã³ã¿ãŽãã¹ãã«é¢ããã
ããã«ãã®ç¯å²åã³é©åæ§ãã以åŸã«ç€ºããã詳现ãªèšèŒããæããã«ãªãããããããªããæ¬çºæã®å¥œãŸããäŸã瀺ããŠãããããã®è©³çŽ°ãªèšèŒããå³ç€ºã ãã®æ段ã«ããæ瀺ããããã®çç±ãšããŠãæ¬çºæã®ç²Ÿç¥åã³ç¯å²å
ã§ã®çš®ã
ã®å€ååã³å€æŽãåœæ¥è
ã«æããã«ãªããã®ãšããŠç解ãã¹ãã§ããã
æ¬çºæã®ä»ã®ç®çãå©ç¹ãåã³ç¹é·ããæ·»ä»å³é¢ãåç
§ã奜ãŸããäŸã®ééå®çèšèŒã«åŸã£ãŠèªã¿åºãããšã«ãŠææã«æããã«ãªãããããäŸç€ºçã§æ¬çºæã®ç¯å²ãéå®ãããã®ãšããŠè§£éãã¹ãã§ãªãã
奜ãŸããäŸã®èšèŒ
æ¬æ现æžã«äœ¿çšãããçšèªãæ確ã«ãããŠççŸç¡ãç解ã§ããããäžèšã®å€ãã®çšèªã®å®çŸ©ãæäŸããã
æ¬æ现æžã«äœ¿çšãããçšèªãæ確ã«ãããŠççŸç¡ãç解ã§ããããäžèšã®å€ãã®çšèªã®å®çŸ©ãæäŸããã
æ¬æ现æžã«äœ¿çšãããçšèªãã¢ãŽãã¹ããã¯ãå°ãªããšã1ã®èŠ³ç¹ã«ãããEP4ã®çç©æŽ»æ§ã®å¹èœãä¿é²ããç©è³ª(agent)ãšããŠç解ããããEP4ã®çç©æŽ»æ§ããããšãã°éçå掻æ§ãåºæ¿ãããããŠã·ã°ãã«äŒéãåºæ¿ããããšã«ãããåã¯éçåEP4ã¿ã³ãã¯è³ªãšã·ã°ãã«äŒéã«ã¹ã±ãŒãã«é¢äžããä»ã®ã¿ã³ãã¯è³ªãšãããå¹æçãªçžäºäœçšãå¯èœã«ããå¢å€§ãããããšãã§ããã
æ¬æ现æžã«äœ¿çšãããçšèªãã¢ã³ã¿ãŽãã¹ããã¯ãå°ãªããšã1ã®èŠ³ç¹ã«ãããEP4çç©æŽ»æ§ãé»å®³ããç©è³ª(agent)ãšããŠç解ããããEP4ã¢ã³ã¿ãŽãã¹ãã¯ãEP4ååãšä»ã®ååãšã®çžäºäœçšãé»å®³ããããåã¯æžå°ãããè¥ããã¯EP4ããªããããã®åæåã³çºçŸãæžå°ãããåã¯EP4ååã®çç©æŽ»æ§ãé»å®³ãããååç©ã§ãã£ãŠããããã¢ã³ã¿ãŽãã¹ãã¯ãEP4ã®ãããã³ãã»ãã¬ãã£ã圢äœãªã©ã®æ žé
žååãEP4ã®ã¢ã³ãã»ã³ã¹ååãEP4ã®mRNAãšç¹ã«çžäºäœçšã®å¯èœãªãªããŸãŒã ãåã¯EP4ããªããããã«çµåããåå(ããšãã°ããããããããããæš¡å£ç©ãæäœãå°åå)ã§ãã£ãŠãããã
æ¬æ现æžã«äœ¿çšãããçšèªãã¢ããé
žãã¯ã倩ç¶ã«ååšããã¢ããé
žã®LåãšDåã®äž¡ç°æ§äœã䞊ã³ã«ããããååŠã«ãŠåæãããããããé¡äŒŒç©ã®èª¿è£œã«äœ¿çšãããä»ã®éã¿ã³ãã¯è³ªæ§ã¢ããé
žãå«ããã®ãšããŠç解ãããã倩ç¶ã«ååšããã¢ããé
žã®äŸã¯ãã°ãªã·ã³ãã¢ã©ãã³ãããªã³ããã€ã·ã³ãã€ãœãã€ã·ã³ãã»ãªã³ãåã³ãã¬ãªãã³ãå«ããããã«éå®ãããªããéã¿ã³ãã¯è³ªæ§ã¢ããé
žã®äŸãšããŠã¯ããã«ãã€ã·ã³ããã«ããªã³ãã·ã¯ãããã·ã«ã»ã¢ã©ãã³ãããã§ãã«ã»ã¢ã©ãã³ããã¢ãã§ãã«ã¢ã©ãã³ããããã«ã¢ã©ãã³ãããªãžã«ã¢ã©ãã³ãåã³çœ®æããããã§ãã«ã»ã¢ã©ãã³(ã¢ã«ã³ãã·ãããã²ã³åã³ãããåºãå«ããããã«éå®ãããªã1åã¯è€æ°ã®çœ®æåºã«ãã眮æ)ãå«ãŸãããããã«éå®ãããªããããã«ããŒã¿åã³ã¬ã³ããŒã»ã¢ããé
žã¯ãçšèªãã¢ããé
žãã®ç¯å²å
ã§ãããããããååç©ããããããååŠã«ãããŠåœæ¥è
ã«åšç¥ã§ããã
èªææ§ã®ç®çãšããŠã以äžã«äžè¬çã«åãå
¥ããããã¢ããé
žã®ç¥èªã瀺ãã
æ¬æ现æžã«äœ¿çšãããçšèªã極æ§ã¢ããé
žãã¯ãæ°Žã«æ¯èŒçè¯ã溶ããéé»è·åŽéãå«ãã¢ããé
žãæããã®ãšããŠç解ãããã
æ¬æ现æžã«äœ¿çšãããçšèªãçæ°Žæ§ã¢ããé
žãã¯ãæ°Žãžã®æº¶è§£ã«ä¹ããéé»è·åŽéãå«ãäœããã®ã¢ããé
žãæããã®ãšããŠç解ãããã
æ¬æ现æžã«çšããããçšèªãé¢é£ã¢ããé
žãã¯ãå
ã®å€©ç¶ã®åã¯åæçã«åŽéã®å®èœæ§ãæ¬æ
(ããšãã°ãè³éŠæãèèªæãè·é»ãããã極æ§ã®H-äŸäžäœãH-å容äœãªã©)ã§ããαãβåã¯Î³äœã«çœ®æãããã¢ããé
žãæããã®ãšããŠç解ãããã眮æåºã®äŸã¯ãè¡š-1ãè¡š-2ã«æäŸããããã®ãå«ããããã«éå®ãããªãã
æ¬æ现æžã«ãŠçžäºã«äº€æã§ããçšèªãçç©åŠç掻æ§ãããçç©æŽ»æ§ãåã¯ãçç©çæ©èœãã¯ãEP4ããªããããåã¯ãã®ä»»æã®æçã«ãŠçŽæ¥çã«åã¯éæ¥çã«è¡ãªãããæ©èœãèšåãããã®ãšããŠç解ããããEP4ã®çç©åŠç掻æ§ã¯ãä»ã®ååãžã®çµåãä»ã®ã¿ã³ãã¯è³ªãšã®çžäºäœçšãGαã¿ã³ãã¯è³ªã«ããã°ã¢ãã³ã»ãã¯ã¬ãªããçµåãªã©ã®ã·ã°ãã«äŒéã®å€åãã«ã«ã·ãŠã æµåº(fluxes)ãcAMPã®åæãã€ãã·ããŒã«ãªã³é
žå¡©ã®åæãä»ã®çŽ°èå
ã¿ã³ãã¯è³ªåã¯çŽ°èèã«ããã被èŠããã(pits)ã«é¢é£ããEP4ããªããããã®å
åšåããªã©ãå«ããããã«éå®ãããªããEP4å容äœã®çç©ã¢ãã»ã€ã®èšèŒã¯ãäžèšã«æäŸãããã
æ¬æ现æžã«ãããŠçžäºã«äº€æã§ããçšèªã现èããã宿䞻现èãåã¯ãçµã¿æã宿䞻现èãã¯ãç¹ç°çãªçŽ°èã°ããããã®å
šãŠã®åå«ãæããŠãããã®ãšããŠç解ããããããã«ãããã®çšèªã®ç¯å²å
ãšããŠç解ããããã®ã¯ãåºä¹³åç©ãäž¡çé¡ãèé¡ãåã³çŽ°èç±æ¥ã®çŽ°èã§ããã
æ¬æ现æžã«äœ¿çšãããçšèªã調ç¯ãã¯ãäžé調ç¯[ããªãã¡æŽ»æ§ååã¯åºæ¿(ããšãã°ãäœåäœçš(agonizing)åã¯ä¿é²äœçš(potentiating)]ãåã³äžé調ç¯[ããªãã¡é»å®³ååã¯æå¶å(ããšãã°æ®æäœçš(antagonizing)ãæžå°äœçšåã¯é»å®³äœçš)]ã®äž¡æ¹ãèšåãããã®ãšããŠç解ãããã
æ¬æ现æžã«çžäºã«äº€æã§ãããã®ãšããŠäœ¿çšãããçšèªãã¿ã³ãã¯è³ªãããããªãããããã¯ãéºäŒåç£çç©ãæããã®ãšããŠç解ãããã
æ¬æ现æžã§äœ¿çšãããçšèªããããããã¯ãå°ãªããšã2ã€ã®ã¢ããé
žããããŠæ倧çŽ50ã®ã¢ããé
žãå«ãçŽééåäœãæããã®ãšç解ãããããã®ã¢ããé
žãã倩ç¶ã«ååšããååãåã¯åæã«ãŠèªå°ãããååã§ãã£ãŠããããããããååã®äŸã¯ãL-ã¢ããé
žãD-ã¢ããé
žãåã³åæã«ãã倩ç¶ã¢ããé
žã®é¡äŒŒç©ãå«ããããã«éå®ãããªãããããããéã¿ã³ãã¯è³ªæ§ã¢ããé
žãå«ããããã«éå®ãããªãã
æ¬æ现æžã«äœ¿çšãããçšèªãããããæš¡å£ç©ãã¯ãããããã®æ§é çåã³ïŒåã¯æ©èœçç¹é·ãç䌌ãŠããååãæããã®ãšç解ããããåœæ¥è
ããçš®ã
ã®æ¹æ³ã䜿çšããŠç¹å®ããããã®ããããæš¡å£ç©ãèªå°ãããããªãã¡ãåã
ã®ã¢ããé
žãšåæã«ããååŠç©è³ªãšã®çœ®æãéã¿ã³ãã¯è³ªæ§ã¢ããé
žã®é¡äŒŒäœãæ¬ å€±åã³ä»å ããŠããã¢ããé
žãããŒã¿ã»ã¿ãŒã³æ¬äœãªã©ã®éªšæ Œ(scaffolds)ãšãåã¯åšç¥ã®ãã¡ãŒãã³ãã©ã¢(pharmacophores)ãšããããã«ããã1åã¯è€æ°ã®ã¢ããé
žãšã®çœ®ãæããªã©ãå«ããããã«éå®ãããªããããããæš¡å£ç©ãåŸãç®çã¯ãå¹åãå¹èœã®ç¹ã§åªããããããã®é¡äŒŒååãåŸãããšããããŠèŠªãããããšæ¯èŒããŠãµã€ãºãããå°ãããè¬çåŠçäžã€æ¯æ§åŠçã«åªãããããã¡ã€ã«(profile)ãæããããšã§ããã
æ¬æ现æžã«äœ¿çšãããçšèªãå°ååãã¯ãçŽ1kDããå°ããååéãããããŠæã奜ãŸããã¯çŽ0.4kDããå°ããååéãæããçµæç©ãæããŠãããšç解ããããå°ååã®äŸãšããŠã¯ããã¯ã¬ãªãããã¢ããé
žããããããããããæš¡å£ç©ãçæ°Žåç©ãè質åã¯ä»ã®ææ©(ççŽ å«æ)ååãå«ãŸãããããã«éå®ãããªãã
æ¬æ现æžã«äœ¿çšãããçšèªãä»ã®çœ®æ矀ãããè¡š2ã«æ瀺ããã5ã€ã®çŸ€ã®ãã¡1矀ã®ç¯å²å
ã«ãŠå€æãããããšãæããŠãããšç解ãããã
æ¬æ现æžã«äœ¿çšãããçšèªãæ£è ãã¯ãããåã³ä»»æã®åç©ãå«ãããã«å¯Ÿãç¹ã«èšåããŠãããšç解ãããã
æ¬æ现æžã«äœ¿çšãããçšèªãæ£è ãã¯ãããåã³ä»»æã®åç©ãå«ãããã«å¯Ÿãç¹ã«èšåããŠãããšç解ãããã
æ¬çºæã¯ã以äžã®äžè¬åŒïŒ
X-R1-R2-R3-R4-R5-R6-R7-Yã
ãæããããããã»ã¢ã³ã¿ãŽãã¹ããå«ãçµæç©ã«é¢ããã
X-R1-R2-R3-R4-R5-R6-R7-Yã
ãæããããããã»ã¢ã³ã¿ãŽãã¹ããå«ãçµæç©ã«é¢ããã
ããã§Xã¯ãããããã®Næ«ç«¯ã«çµåããããããŠæ°ŽçŽ ååã䞊ã³ã«ã«ã«ãã¡ãŒãåã³ã¢ã·ã«åºãªã©ã®ä¿è·åºããæã矀ããéžæããããã¢ã·ã«åºã¯ãã·ã¯ãããã·ã«ããã§ãã«ããã³ãžã«ãåã³1ä¹è³8ã®ççŽ ååãç¯å²ãšããçãçŽéåã³åå²éã¢ã«ãã«åºããæã矀ããéžæãããçæ°Žæ§æåããæ§æããããã¢ã·ã«åºã®å
·äœäŸã¯ãã¢ã»ãã«åã³ãã³ãžã«åºã§ããïŒ
Yã¯ãããããã®ã«ã«ããã·æ«ç«¯ã«çµåããããããŠæ°ŽçŽ ååã1ä¹è³3ã®L-ãªã·ã³æ®åºãã°ãªã·ã³ããªã³é žå¡©ãç¡«é žå¡©åã³ã¢ããããæã矀ããéžæãããïŒ
R1ã¯ãL-(4,4)ããã§ãã«ã¢ã©ãã³åã³D-(4,4)ããã§ãã«ã¢ã©ãã³ããæã矀ããéžæããïŒ
R2ã¯ãThrã§ããïŒ
R3ã¯ãSerã§ããïŒ
R4ã¯ãTyrããã³Pheããæã矀ããéžæããïŒ
R5ã¯ãGluããã³Aspããæã矀ããéžæããïŒ
R6ã¯ãAla,Gly,ããã³Serããæã矀ããéžæããïŒãããŠ
R7ã¯ãLeu,lle,Valããã³Lysããæã矀ããéžæãããã
Yã¯ãããããã®ã«ã«ããã·æ«ç«¯ã«çµåããããããŠæ°ŽçŽ ååã1ä¹è³3ã®L-ãªã·ã³æ®åºãã°ãªã·ã³ããªã³é žå¡©ãç¡«é žå¡©åã³ã¢ããããæã矀ããéžæãããïŒ
R1ã¯ãL-(4,4)ããã§ãã«ã¢ã©ãã³åã³D-(4,4)ããã§ãã«ã¢ã©ãã³ããæã矀ããéžæããïŒ
R2ã¯ãThrã§ããïŒ
R3ã¯ãSerã§ããïŒ
R4ã¯ãTyrããã³Pheããæã矀ããéžæããïŒ
R5ã¯ãGluããã³Aspããæã矀ããéžæããïŒ
R6ã¯ãAla,Gly,ããã³Serããæã矀ããéžæããïŒãããŠ
R7ã¯ãLeu,lle,Valããã³Lysããæã矀ããéžæãããã
æ¬çºæã®å¥œãŸããäŸã«ãããŠãæ¬çºæã®ããããã»ã¢ã³ã¿ãŽãã¹ãã¯ã213.15(bip)tsyeal(é
åçªå·1)ïŒ213.19(bip)tsyealk(é
åçªå·2)ïŒ213.20(bip)tsyeglk(é
åçªå·3)ïŒ213.21(bip)tsyealKK(é
åçªå·4)ïŒ213.22(bip)tsyeglKK(é
åçªå·5)ïŒ213.23(bip)tsyeslK(é
åçªå·6)ïŒ213.24(bip)tsyeslKK(é
åçªå·7)ïŒ213.25(bip)tsyeaK(é
åçªå·8)ïŒ213.26(bip)tsyesK(é
åçªå·9)ïŒ213.27(Bip)tsyealKK(é
åçªå·10)ïŒ213.28(bip)tsyeaLKK(é
åçªå·11)ïŒ213.29(Bip)tsyeaLKK(é
åçªå·12)ïŒ213.30(bip)tsyealGKK(é
åçªå·13)ããæã矀ããéžæãããã
ããã§ãBipã¯ãL-(4,4)-ããã§ãã«ã¢ã©ãã³ã§ãbipã¯ãD-(4,4)-ããã§ãã«ã¢ã©ãã³ã§ããããŠããã§D-ã¢ããé
žã¯å°æåã§ç€ºãããL-ã¢ããé
žã¯å€§æåã«ãŠç€ºããããã¢ããé
žãåäžã®æåã³ãŒãã«ãŠç€ºããããã«æ¬çºæã¯ã糞çäœæ¿Ÿéåã³å°¿æåºãå¢å€§ãããããã®å»è¬çã«åãå
¥ãå¯èœãª1åã¯è€æ°ã®æ
äœåã¯è³Šåœ¢å€ãšé¢é£ããæšèåãããé
åçªå·1ä¹è³13ãåã³ãã®ããããæš¡å£ç©ããæã矀ããéžæããã1åã¯è€æ°ã®ããããã»ã¢ã³ã¿ãŽãã¹ããå«ãå»è¬çµæç©ã«é¢ãããããã«æ¬çºæã¯ã1åã¯è€æ°ã®å»è¬çã«åãå
¥ãå¯èœãªæ
äœåã¯è³Šåœ¢å€ãšé¢é£ããæšèåãããé
åçªå·1ä¹è³13ãåã³ãã®ããããæš¡å£ç©ããæã矀ããéžæããã1åã¯è€æ°ã®ããããã»ã¢ã³ã¿ãŽãã¹ããå«ãå»è¬çµæç©ã«é¢ããã
ããã«æ¬çºæã¯ãæ«æã®è
èçŸæ£ãåã³æ¥æ§è
äžå
šãšèšºæãããæ£è
ã®ç³žçäœæ¿Ÿéãåã³å°¿æåºãæ¹è¯ããããã®æšèåãããé
åçªå·1ä¹è³13åã³ãã®ããããæš¡å£ç©ããæã矀ããæã矀ããéžæããã1åã¯è€æ°ã®ããããã»ã¢ã³ã¿ãŽãã¹ããå«ãå»è¬çµæç©ã®äœ¿çšã«é¢ããã
ããã«æ¬çºæã¯ã骚ç²é¬çãæ¯ã®çŸæ£ãåã³ã¬ã³é¢é£ã®çç¶ã«çœ¹ã£ãŠããæ£è
ãçµéšãã骚ã®æå·ãé²æ¢ããããã«ãæšèåãããé
åçªå·1ä¹è³13åã³ãã®ããããæš¡å£ç©ããæã矀ããéžæããã1åã¯è€æ°ã®ããããã»ã¢ã³ã¿ãŽãã¹ããå«ãå»è¬çµæç©ã®äœ¿çšã«é¢ããã
ããã«æ¬çºæã¯ãè¡ç®¡éåçãçºçããå»è¬çç¶ã«ãããåè管ã®ééãè¡ãªãããã®æšèåãããé
åçªå·1ä¹è³13åã³ãã®ããããæš¡å£ç©ããæã矀ããéžæããã1åã¯è€æ°ã®ããããã»ã¢ã³ã¿ãŽãã¹ããå«ãå»è¬çµæç©ã®äœ¿çšã«é¢ããã
ããã«ãæ¬çºæã¯ãçµè
žã¬ã³åã¯è
ºè
«çæ§ããªãŒããšèšºæãããæ£è
ãäºé²åã¯æ²»çããããã«ãæšèåãããé
åçªå·1ä¹è³13åã³ãã®ããããæš¡å£ç©ããæã矀ããéžæããã1åã¯è€æ°ã®ããããã»ã¢ã³ã¿ãŽãã¹ããå«ãå»è¬çµæç©ã®äœ¿çšã«é¢ããã
ããã«æ¬çºæã¯ãããã¹ã¿ã°ã©ã³ãžã³E2ã®å容äœEP2ã倩ç¶åã¯çµã¿æãçã«çºçŸãã现èåã¯çµç¹ãå¹é€ããå·¥çšãåèšå容äœã«ãããåšç¥æ¿åºŠã®ã¢ãŽãã¹ãã®ååšåã¯éååšäžã§ãè«æ±é
1ã®æå®éã®ååç©ã«ãŠå¹é€ããã现èåã¯çµç¹ãåŠçããå·¥çšããããŠå容äœã®çç©æŽ»æ§ã®1åã¯è€æ°ã®åèšèŠ³ç¹ã枬å®ããå·¥çšãå«ã芳ç¹ã«ãããŠãããã§åèšèŠ³ç¹ããGαã¿ã³ãã¯è³ªã«ããGTPã®çµååã³å æ°Žå解ãç°ç¶ã¢ããã·ã³ïŒãªã³é
žã®åæã现èäžã®ã«ã«ã·ãŠã ã®å€åã现èã®å¢æ®åã³ïŒåã¯ååãå€æŽãããéºäŒåçºçŸãåã³å¹³æ»çã®åçž®åã¯æ¡åŒµããæã矀ããéžæããããæ¬çºæã®ããããåã¯ããããæš¡å£ç©ã䜿çšããæ¹æ³ã«é¢ããã
æåŸã«æ¬çºæã¯ãå°ååæ¬äœãåå®ããããã®çç©åææ³ã«ãããŠãæšèåãããé
åçªå·1ä¹è³13ããæã矀ããéžæããã1åã¯è€æ°ã®ããããã»ã¢ã³ã¿ãŽãã¹ãã®äœ¿çšã«é¢ããã
ãã¡ãããæ¬çºæã®ããããã»ã¢ã³ã¿ãŽãã¹ãããããã¹ã¿ã°ã©ã³ãžã³E2ã®å容äœEP4ã®ã¢ã³ã¿ãŽãã¹ãã«ãã蚌æãããå»è¬çç¶åã¯çŸæ£ã®é²æ¢ã«äœ¿çšã§ããããšãç解ãã¹ãã§ããã
EP4ã¢ã³ã¿ãŽãã¹ã
æ¬çºæã«ãããŠãïŒçµã®ãããããã213.15(é åçªå·1)ã®é åã«åºã¥ããŠåæãããã溶解æ§ãäœãããšã«ããæ²»çå€ãšããŠã®æ¬ããããã®å¹èœãå¶éãããããããã213.15ã®å皮修食ãå«ãããããã©ã€ãã©ãªãŒãåæããããããŠéåžžã®åç©åã³æ¥æ§è èäžå šã®ã©ããã®ã¢ãã«ã®è¡æž ã®å解ã溶解æ§ãåã³å»è¬å¹èœåã³å¹åã®ç¹ã§ç¹åŸŽä»ããããããããã®åææ³ã«åºã¥ããŠå¹Ÿã€ãã®ããããé¡ãããå ·äœçã«ã¯é åçªå·2ä¹è³13ã®äžèŠ§ã«èšèŒãããããããé¡ãåå®ãããã
æ¬çºæã«ãããŠãïŒçµã®ãããããã213.15(é åçªå·1)ã®é åã«åºã¥ããŠåæãããã溶解æ§ãäœãããšã«ããæ²»çå€ãšããŠã®æ¬ããããã®å¹èœãå¶éãããããããã213.15ã®å皮修食ãå«ãããããã©ã€ãã©ãªãŒãåæããããããŠéåžžã®åç©åã³æ¥æ§è èäžå šã®ã©ããã®ã¢ãã«ã®è¡æž ã®å解ã溶解æ§ãåã³å»è¬å¹èœåã³å¹åã®ç¹ã§ç¹åŸŽä»ããããããããã®åææ³ã«åºã¥ããŠå¹Ÿã€ãã®ããããé¡ãããå ·äœçã«ã¯é åçªå·2ä¹è³13ã®äžèŠ§ã«èšèŒãããããããé¡ãåå®ãããã
EP4ã¢ã³ã¿ãŽãã¹ã213.15(é
åçªå·1)ã®æé©å
æ¬çºæã®ããããèªå°ååç©ã®æ²»çå¹æãæ¹è¯ããããããã®å¹Ÿã€ãã®ä¿®é£Ÿãã1æ¹ã®ã¢ããé žãšé¢é£ããã¢ããé žãšã®çœ®æã«ãããåã¯ããããã®ã«ã«ããã·æ«ç«¯ãžã®ã¢ããé žã®ä»å ã«ããè¡ããããæ¬çºæã®EP4ããããã»ã¢ã³ã¿ãŽãã¹ãã®ã¢ããé žã®çœ®æã«ã¯ãããªããããã«ãããå°ãªããšã1ã®ã¢ããé žæ®åºããæ§é ãåã¯åŽéã®å®èœåº(è³éŠæãèèªæããããŠæ£åã¯è² ã«è·é»ããã)ã®ããããã§é¢é£ãããç°ãªã£ãã¢ããé žã«ãŠçœ®æãããããªã¢ã³ããå«ãŸãããããã«éå®ãããªãããããã眮æäœã¯ãã¢ããé žé¢ä¿ã®ä»¥äžã®èšèŒã«åŸã£ãŠè¡ãªãããããšã奜ãŸããã
æ¬çºæã®ããããèªå°ååç©ã®æ²»çå¹æãæ¹è¯ããããããã®å¹Ÿã€ãã®ä¿®é£Ÿãã1æ¹ã®ã¢ããé žãšé¢é£ããã¢ããé žãšã®çœ®æã«ãããåã¯ããããã®ã«ã«ããã·æ«ç«¯ãžã®ã¢ããé žã®ä»å ã«ããè¡ããããæ¬çºæã®EP4ããããã»ã¢ã³ã¿ãŽãã¹ãã®ã¢ããé žã®çœ®æã«ã¯ãããªããããã«ãããå°ãªããšã1ã®ã¢ããé žæ®åºããæ§é ãåã¯åŽéã®å®èœåº(è³éŠæãèèªæããããŠæ£åã¯è² ã«è·é»ããã)ã®ããããã§é¢é£ãããç°ãªã£ãã¢ããé žã«ãŠçœ®æãããããªã¢ã³ããå«ãŸãããããã«éå®ãããªãããããã眮æäœã¯ãã¢ããé žé¢ä¿ã®ä»¥äžã®èšèŒã«åŸã£ãŠè¡ãªãããããšã奜ãŸããã
è¡šïŒïŒé¢é£ã¢ããé
žã®äŸ
è¡š2ã«ç€ºãããã«ãæ¬çºæã®ããããEP4ã¢ã³ã¿ãŽãã¹ãã®å¥ã®çœ®æåºã¯ãå°ãªããšã1ã®ã¢ããé
žæ®åºãé€å»ããããããŠéã£ãæ®åºã«ãŠçœ®æãããŠããããŠæå®ã®äœçœ®ã«æ¿å
¥ãããããšãå
å«ããã
è¡š2ã®ã«ãã³å
ã«èšèŒããã3çš®ã®ã¢ããé
žæ®åºããã¿ã³ãã¯è³ªã®æ§æã«ç¹å¥ãªåœ¹å²ãæãããŠããããGlyãã¯åŽéãæ¬ ãå¯äžã®æ®åºã§ããããã®çµæéã«æè»æ§ããããããããããªããããã¯ãαããªãã¯ã¹æ§é 以å€ã®2次æ§é ã®çæãä¿é²ããåŸåãããããã®åœ¢ç¶ãããProãã¯ãéããã£ãããšææãããããã¯é垞βã¿ãŒã³æ§æ§é ãä¿é²ããåŸåãããããCysãã¯ãžã¹ã«ãã£ãçµå圢æã«é¢äžããããšãã§ããã
æœåšçã«æ°ŽçŽ ãšçµåå¯èœãªãTyrãã¯ããSerãåã³ãThrããšææãªé¡äŒŒæ§ãæããã
æ¬çºæã®EP4ããããã¢ã³ã¿ãŽãã¹ãã®ããããã®ã¢ããé
žæåããããã«å¯Ÿå¿ããé¡åç°æ§äœ(enantiomer)(åãã¢ããé
žã§ããããã©ãªãã£ãŒãå察)ã«ãã眮æããããšãã§ããããã®ããã倩ç¶ã«ååšããL-æ§é äœã®ã¢ããé
žãã察å¿ããé¡åç°æ§äœ(enantiomer)ã«ãŠçœ®æããããããªãã¡ã¢ããé
žãD-æ§é äœãæããããšã«ãªããL-æ§é äœã®ã¢ããé
žã¯ãDæ§é äœã®ã¢ããé
žãšåãååŠæ§é äœã§ããããå察ã®ãã©ãªãã£ãŒ(chirality)ãæãããããã«L-åã³D-äœã®é
眮ã¯ãR-åã¯S-åã®é
眮ãšããŠéåžžèšåãããŠãããè¿œå çãªããªãšãŒã·ã§ã³ãšããŠã¯ãç°ãªã空éæ§æã®ååŠçŸ€ãæäŸããβ-åã³Î³-ã¢ããé
žããããããã
äžèšã®çœ®æã«å ããããã«æ©èœçã«é¡äŒŒããåŽéãæäŸããåæã¢ããé
žããããããäžã«å°å
¥ããããšãã§ãããããšãã°ãè³éŠæã¢ããé
žããD-åã¯L-ãããã«ã¢ã©ãã³ãD-åã¯L-ãã§ãã«ã°ãªã·ã³ãD-åã¯L-2-ããšãã«ã¢ã©ãã³ãD-åã¯L-1-,2-,3-,åã¯4-ãã¬ãã«ã¢ã©ãã³ãD-åã¯L-3-ããšãã«ã¢ã©ãã³ãD-åã¯L-(2-ããªãžãã«)-ã¢ã©ãã³ãD-åã¯L-(3-ããªãžãã«)-ã¢ã©ãã³ãD-åã¯L-(2-ãã©ãžãã«)-ã¢ã©ãã³ãD-åã¯L-(4-ã€ãœãããã«)-ãã§ãã«ã°ãªã·ã³ãD-(ããªãã«ãªãã¡ãã«)-ãã§ãã«ã°ãªã·ã³ãD-(ããªãã«ãªãã¡ãã«)-ãã§ãã«ã¢ã©ãã³ãD-p-ãã«ãªããã§ãã«ã¢ã©ãã³ãD-åã¯L-p-ããã§ãã«ã¢ã©ãã³ D-åã¯L-p-ã¡ããã·ããã§ãã«ã¢ã©ãã³ãD-åã¯L-2-ã€ã³ããŒã«(ã¢ã«ãã«)ã¢ã©ãã³ãåã³D-åã¯L-ã¢ã«ãã«ã¢ã©ãã³ãªã©ã«ãŠçœ®æããããšãã§ããããã§ã¢ã«ãã«åºãã眮æåã¯é眮æã®ã¡ãã«ããšãã«ããããã«ãããã·ã«ãããã«ããã³ãã«ãã€ãœãããã«ãã€ãœ-ããã«ãåã³ã€ãœ-ãã³ãã«ããæã矀ããéžæãããã
éã«ã«ãã³é
žç³»ã¢ããé
žãããªã³é
žåãåã¯ç¡«é
žå(ããšãã°ã-SO3H)ããã¢ããé
žãæäŸãããããã«ãè² ã®è·é»ãæããããçæãããããééå®äŸãšããŠèããããã
ä»ã®çœ®æåºã¯ã倩ç¶ã®ã¢ããé
žãšã¢ã«ãã«åºãçµåããŠçæãããé倩ç¶ã®ã¢ã«ãã«åã¢ããé
žãå«ãããªã·ã³åã³ã¢ã«ã®ãã³ãªã©ã®å€©ç¶ã®å¡©åºæ§ã¢ããé
žããã¢ãã³(NH2)ã®å®èœåºã§ã¢ã«ãã«åºãšçœ®æããããšãã§ãããããã«ä»ã®çœ®æåºãšããŠã¯ãã¢ã¹ãã©ã®ã³åã¯ã°ã«ã¿ãã³ã®ãããªã«èªå°äœ(ããšãã°ãCONH2ã®å®èœåºã«ä»£ãCN-æåãå«æãããïŒãã¡ããªãã³ã®ã¹ã«ããã·ãèªå°äœãããããããããã«ããããã«çµåããããããã®ã¢ããããã±ãã¡ãã¬ã³ãããããã·ãšãã«ããšãã«/éå
ã¢ãããããªã¢ãããåã¯éæ¹åã«é
眮ããã(reversed)ã¢ããæå(ããšãã°ã((-C=O)-NH-)ã«å¯Ÿã(-C=O)-CH2-),(-CHOH)-CH2-),(CH2-CH2-),(-C=S)-NH-)ãåã¯-NH-(-C=O))ã«ãŠçœ®ãæããããšãã§ããã
åŸã£ãŠå
±æçµåã«ãŠä¿®é£Ÿããããããã¯ãæ¬çºæã®ç¯å²å
ã«å«ãŸããããããã修食ããããªããããã®éžæãããåŽéåã¯æ«ç«¯æ®åºãšåå¿å¯èœãªææ©èªå°ç©è³ªãšãæšçãšãããããªããããã®ã¢ããé
žæ®åºãšãåå¿ãããããšã«ãããEP4ããããã¢ã³ã¿ãŽãã¹ãã«å°å
¥ããããšãã§ãããååŠèªå°ç©è³ªã®ä»¥äžã®äŸã¯å³ç€ºã ãã®æ¹æ³ã«ãŠæäŸãããããæ¬çºæã®ç¯å²ãéå®ããæå³ã¯ãªããã·ã¹ãã€ã³æ®åºãã2-ã¯ããé
¢é
žåã¯ã¯ããã¢ã»ãã¢ãããªã©ã®Î±-ããã²ã³åé
¢é
ž(åã³çžåœããã¢ãã³)ãšåå¿ããã«ã«ããã·ã¡ãã«åã¯ã«ã«ããã·ã¢ããã¡ãã«èªå°äœãåŸãããããã¹ããžã³æ®åºãããžãšãã«ããã«ã«ãã³é
ž(ããšãã°ãpH5.5ä¹è³7.0ã§)ãªã©ã®ååç©ãšåå¿ãããããšã«ããèªå°å¯èœã§ããããã®çç±ã¯æ¬è©Šè¬ãããã¹ããžã³åŽéã«æ¯èŒçç¹ç°çãªããã§ãããããã«p-ããã¢ãã§ãã·ã«ã»ããããã䜿çšããããšãã§ãã(ããšãã°ãåå¿ãpH6.0ã§0.1Mã®ã«ã³ãžã«é
žãããªãŠã (sodium cacodylate)ã«ãŠè¡ãããšã奜ãŸãã)ããªã·ã³åã³ã¢ããæ«ç«¯æ®åºããç¡æ°Žã³ãã¯é
žãåã¯ä»ã®ã«ã«ãã³é
žç¡æ°Žç©ãªã©ã®ååç©ãšåå¿ãããããšãã§ãããα-ã¢ããé
žå«ææ®åºãèªå°ããä»ã®é©åãªè©Šè¬ãšããŠã¯ãã€ãããšã¹ãã«(ããšãã°ãã¡ãã«ãã³ãªã³ã€ããã€ã)ãªã©ã®ååç©ïŒããªãããµãŒã«ãªã³é
žãããªãããµãŒã«ãã¯ãããããã€ãã©ã€ããããªããããã³ãŒã³ã¹ã«ãã³é
žãO-ã¡ãã«ã€ãœãŠã¬ã¢ã2,4ãã³ã¿ã³ãžãªã³åã³ãã©ã³ã¹ã¢ãããŒãŒã«ããã°ãªãªãã·ã¬ãŒããšã®è§Šåªåå¿ç©ããããããã
ã¢ã«ã®ãã³æ®åºããåšç¥æ¹æ³ã®å·¥çšã«ããããã§ãã«ã°ãªãªããµãŒã«ã2,3-ãã¿ã³ãžãªã³ã1,2-ã·ã¯ããããµã³ãžãªã³ãåã³ãã³ãããªã³ãªã©1åã¯å¹Ÿã€ãã®åžžçšã®è©Šè¬ãšã®åå¿ã«ãã修食ãããããšãã§ãããã¢ã«ã®ãã³æ®åºã®èªå°åããã°ã¢ãžãã³å®èœåºã®pKaãé«ãããšãããã¢ã«ã«ãªæ¡ä»¶äžã«ãŠãã®åå¿ãè¡ãªãå¿
èŠããããããã«ããããã®è©Šè¬ã¯ããªã·ã³ã®ã¢ããåºãåã³ã¢ã«ã®ãã³ã®Îµã¢ããåºãšãåå¿å¯èœã§ããã
ããã·ã³æ®åºããèªäœã®ç¹ç°ç修食ã¯è¯ãç¥ãããŠãããç¹ç°çã§ãããŠéå¶éã®äŸãšããŠã¯ãè³éŠæãžã¢ãŸããŠã ååç©åã¯ããã©ãããã»ã¡ã¿ã³ãšã®åå¿ã«ããããã·ãã«æ®åºäžã®ã¹ãã¯ããæšèã®å°å
¥ãããããããN-ã¢ã»ãã«ã€ãããŸã«åã³ããã©ãããã¡ã¿ã³ã䜿çšããO-ã¢ã»ãã«ã»ããã·ãã«çš®åã³3-ãããèªå°äœã®ãããããçæããããšãã§ããã
ã«ã«ããã·ã«åŽéåº(ã¢ã¹ãã«ãã«åã¯ã°ã«ã¿ãã«)ãã1-ã·ã¯ãããã·ã«-3-(2-ã¢ã«ãã©ãªãã«-(4-ãšãã«)ã«ã«ããžã€ããåã¯1-ãšãã«-3-(4-ã¢ãŸãã¢-4,4-ãžã¡ãã«ãã§ãã«)ã«ã«ããžã€ãããªã©ã®ã«ã«ããžã€ãã(R'-N=C=N-R')ãšåå¿ããããšã«ããéžæçã«ä¿®é£Ÿããããšãã§ãããããã«ã¢ã¹ãã«ãã«åã³ã°ã«ã¿ãã«æ®åºããã¢ã³ã¢ããŠã ã€ãªã³ãšåå¿ãããŠã¢ã¹ãã©ã®ãã«åã³ã°ã«ã¿ããã«æ®åºã«å€æã§ãããã°ã«ã¿ããã«åã³ã¢ã¹ãã©ã®ãã«æ®åºã¯ãçžåœããã°ã«ã¿ãã«åã³ã¢ã¹ãã«ãã«æ®åºãžè±ã¢ããåãããã
æ¬çºæã®ããããã®ä»ã®ä¿®é£Ÿã«ã¯ãæè¡çã«åšç¥ãªæ¹æ³ã«ãããããªã³åã³ãªã·ã³ã®æ°Žé
žåãã»ãªã«åã¯ã¹ã¬ãªãã«æ®åºã®æ°Žé
žåºã®ãªã³é
žåããªã·ã³ãã¢ã«ã®ãã³åã³ãã¹ããžã³ã®Î±ã¢ããåºã®ã¡ãã«åãN-æ«ç«¯ã¢ãã³ã®ã¢ã»ãã«åãäž»èŠéã¢ããæ®åº(åã¯N-ã¡ãã«ã¢ããé
žã«ãŠçœ®æ)ã®ã¡ãã«åãåã³å¹Ÿã€ãã®äŸã«ãããC-æ«ç«¯ã«ã«ããã·ã«åºã®ã¢ããåããããããã
èèªé
ž(C6-C18)ãæ¬çºæã®ããããã«å
±æçµåããããšãä»å çãªçç©ç¹æ§ãäžããããããšãã°ããããã¢ãŒãŒèæ§ãè¡æŒ¿ã¿ã³ãã¯è³ªã®çµåãè¡æŒ¿åæžæã®å¢å€§ãåã³çŽ°èå
ãžã®è²«éãªã©ããããããã
修食ã®å¯èœæ§ã®ãããªãŒã(lead)ããããã®äžèšèª¬æã¯ããã®æ¹æ³ã®ç¯å²ãéå®ãããã®ãšã¿ãªãããã¹ãã§ã¯ãªãããŸããé³åãšããŠã®213.15ãªã©ã®ãªãŒã(lead)ããããã䜿çšããŠæäœã§ããå¯èœã®ãã修食ãéå®ãããã®ãšã¿ãªãããã¹ãã§ãªããããããã®æãç³ã¿ã®è€éãªæ§è³ªã«ããããããã»ã¢ã³ã¿ãŽãã¹ãã®å容äœçµåã®æ§æ(conformation)ããEP4çç©æŽ»æ§ã«åãŒã修食ããããã®åœ±é¿ãã絶察çãªç¢ºå®æ§ããã£ãŠäºæž¬ããããšãã§ããªããåŸã£ãŠä¿®é£Ÿããããããã®çç©æŽ»æ§ã確èªããããã®æ¬çºæã«èšèŒãããçç©ã¢ãã»ã€ã«ãããŠåã¯åœæ¥è
ã«æè¡çã«åšç¥ãªãã®ã«ãããŠãçç©æŽ»æ§ã®ç¢ºèªããããè©Šéšãã¹ãããšã¯ãåœæ¥è
ã容æã«ç解ã§ããããã¢ãã»ã€ã®éå¶éäŸãšããŠã¯ãçžåœããGPCRã«çµåããå容äœãåã¯çµåãããªã¬ã³ãã®èª¿ç¯ãããããããGPCRs ã«é¢ä¿ãããããŠããå
·äœçã«ã¯in vitro,ex vivo åã³in vivoã¢ãã»ã€ã®ããã®EP4å容äœã«é¢ä¿ããå
·äœäŸããåœæ¥è
ã«åšç¥ã§ããããŠãã®éžæãããäŸãå³ã«æ瀺ããããã«ä»¥äžã«èšèŒããã
EP4å容äœçç©ã¢ãã»ã€
EP4ããç°çš®æ§çŽ°èãé µæ¯ãåã¯åºä¹³åç©ã®çºçŸç³»ã§ãçµã¿æãçã«çºçŸãããçµç¹åã¯çŽ°èãããEP4ã®ç²Ÿè£œã«ããããç²è£œã®ããããã«ãã調補ç©ã®EP4ã(ç¡çŽ°èã¢ãã»ã€ïŒä»¥äžãåç §)ãçšããŠçç©æŽ»æ§ãè©äŸ¡ããå€ãã®å ¬éãããæ¹æ³ãããã
EP4ããç°çš®æ§çŽ°èãé µæ¯ãåã¯åºä¹³åç©ã®çºçŸç³»ã§ãçµã¿æãçã«çºçŸãããçµç¹åã¯çŽ°èãããEP4ã®ç²Ÿè£œã«ããããç²è£œã®ããããã«ãã調補ç©ã®EP4ã(ç¡çŽ°èã¢ãã»ã€ïŒä»¥äžãåç §)ãçšããŠçç©æŽ»æ§ãè©äŸ¡ããå€ãã®å ¬éãããæ¹æ³ãããã
ç¡çŽ°èã¢ãã»ã€ã¯ãEP4ã¿ã³ãã¯è³ªãšçžäºäœçšããããã«ããEP4ã¿ã³ãã¯è³ªã®æŽ»æ§ã修食ã§ããååç©ã®åå®ã«äœ¿çšå¯èœã§ãããããšãã°ããããååç©ã¯ãEP4ã¿ã³ãã¯è³ªãæ§é çã«ä¿®é£Ÿãããã«ãã掻æ§ã«åœ±é¿ãåãŒãããšãã§ãããããã«ç¡çŽ°èã¢ãã»ã€ããEP4ã¿ã³ãã¯è³ªãšEP4çµåããŒãããŒãšã®çžäºäœçšã調ç¯ããååç©ãåå®ããããã«äœ¿çšããããEP4çµåã®ããŒãããŒã¯PGE2ã§ãããç¹ã«å¥œãŸããäŸã«ãããŠããããååç©ã®åå®ã«äœ¿çšãããç¡çŽ°èã¢ãã»ã€ã¯ãç¹ã«ç·©è¡æº¶æ¶²ãEP4ã¿ã³ãã¯è³ªãEP4çµåããŒãããŒãåã³è©Šéšååç©ãå«ãæ··åç©ããæããè©Šéšååç©ã¯ãããšãã°ãããããããããæš¡å£ç©ãå°ååãåã³æ žé
žã§ãã£ãŠããããæ€åºã®ããçµåããŒãããŒã¯ãæŸå°æ§æ žçš®ãªã©ã®ç¹ç°çããŒã«ãèå
æ§ååç©åã¯é
µçŽ ã«ãŠæšèåã§ããã次ãã«EP4ã¿ã³ãã¯è³ªãšè©Šéšååç©ãšã®çžäºäœçšã¯ãã€ã³ãã¥ããŒã·ã§ã³å·¥çšããããŠæŽæµå·¥çšã®åŸã«æšèã¬ãã«ã®æ±ºå®ã«ãŠæ€åºããããšãã§ãããè©Šéšååç©ã®ååšäžã§ã®EP4ãšEP4çµåã¿ã³ãã¯è³ªãšã®çžäºäœçšã«å¯Ÿãè©Šéšååç©ã®éååšäžã§ã®çžäºäœçšãšã®çµ±èšçã«ææãªå€å(å¢åŒ·åã¯é»å®³)ããè©Šéšååç©ã«å¯ŸããEP4çç©æŽ»æ§ã®ä¿é²çã¢ãŽãã¹ãå¹æ(æ¬äœãåã¯å¢åŒ·å€)åã¯ã¢ã³ã¿ãŽãã¹ãå¹æ(é»å®³)ã瀺ããæŸå°æ§æšèåè©Šæããã·ã³ãã¬ãŒã·ã§ã³åå
å
床èšã«ãŠèšæ°ããããšã§å®éå¯èœã§ãããçµåãªã¬ã³ãããã¢ã»ãã«ã³ãªã³ã»ãšã¹ãã©ãŒãŒãªã©ã®é
µçŽ ãšçµåãããããšãã§ãããããŠçµåãããEP4çµåããŒãããŒããé
µçŽ ã¢ãã»ã€ã«ãŠå®éããããšãã§ããã
ããã«ç¡çŽ°èã¢ãã»ã€ã¯ãEP4ã¿ã³ãã¯è³ªãšçžäºäœçšããããŠEP4ã¿ã³ãã¯è³ªã®æŽ»æ§ã調ç¯ããååç©ãåå®ããããã«äœ¿çšããããåŸã£ãŠäžäŸã«ãããŠãEP4ã¿ã³ãã¯è³ªãšè©Šéšååç©ãšãæ¥è§ŠããããããŠEP4ã¿ã³ãã¯è³ªã®çç©æŽ»æ§ãã¢ãã¿ãŒãããç¡çŽ°èã¢ãã»ã€ã«ãããEP4ã¿ã³ãã¯è³ªã®çç©æŽ»æ§ã¯ãGTPã®çµåãGTPã®å æ°Žå解ãGαã¿ã³ãã¯è³ªã®è§£é¢ãã¢ããã«ã»ã·ã¯ã©ãŒãŒã®æŽ»æ§åããã¹ããªããŒãŒ(A2,βãγãåã³Dåç°æ§äœ)ã®æŽ»æ§åããªã³è質å æ°Žå解ãåã³cAMPåæãªã©ããããããããã«éå®ãããªããããããGPCRã¿ã³ãã¯è³ªã®çç©æŽ»æ§ã®å€åã枬å®ããæ¹æ³ã¯ãåœæ¥è
ã«ååã«ç¥ãããŠããã
EP4çç©æŽ»æ§ã®çŽ°èãåºç€ãšããã¢ãã»ã€
ããã«EP4ã®çç©æŽ»æ§ã¯ã现èãé µæ¯ãäž¡çé¡è¥ããã¯åºä¹³é¡ã®å šäœã«ããã现è(äžèšã®çŽ°èããŒã¹ã¢ãã»ã€(cell-based assays)ãåç §ã®ããš)ã«ãŠãEP4ã¿ã³ãã¯è³ªãã倩ç¶ã¿ã³ãã¯è³ªåã¯èåã¿ã³ãã¯è³ªãšããŠçµã¿æãçºçŸããã(ããšãã°ãæäœãšãããŒãã»ã¿ã°ãç·è²èå ã¿ã³ãã¯è³ªãGαåã¯Î²-ã¢ã¬ã¹ãã³ã«æ¥åããEP4)åèšçŽ°èãçšããŠæž¬å®ããããšãã§ãããèåã¿ã³ãã¯è³ªã¯ã倩ç¶ã®ã¿ã³ãã¯è³ªãã幟ã€ãã®å©ç¹ããããå³ã¡èåã¿ã³ãã¯è³ªãã现èãçµç¹ãåã³çäœå ã®EP4ããªããããåã¯EP4ã®çç©æŽ»æ§ãçŽæ¥æ€åºã§ããããšãããŒã(FLAG,HA,polyHIS,c-mycç)ã¿ã°ä»ã(tagged)EP4ã¯ãå ç«ååŠæè²æ³ã«ãã现èåã³çµç¹å ã¿ã³ãã¯è³ªã®ãã©ããã³ã°ã«æå¹ã§ããããããŠå ç«èŠªåæ§ã¯ãããã°ã©ãã£ãŒãä»ãçŽç²ãåã¯å®è³ªçã«çŽç²ãªEP4ã¿ã³ãã¯è³ªã®åé¢ã®æ¯æŽãšãªãåŸããEP4ã¿ã³ãã¯è³ªã«èåãããç·è²èå ã¿ã³ãã¯è³ª(GFP)ã¯ãããšãã°çãã现èåã¯åºå®çŽ°èã«ãããŠä»ã®çŽ°èã¿ã³ãã¯è³ªãšã®åéåã¯äŒåããšã³ããµã€ãã·ãŒã¹å°èå ã§ã®å åšåã移å(trafficking)ãå解ãªã©ã®EP4ã¿ã³ãã¯è³ªã®äœçœ®ä»ãããããŠãã®ç§»åã®è¿œè·¡ã«äœ¿çšããããšãã§ãããGFPåã³èé žã®èåEP4ãããã€ããŒåã³ãªãªãŽããŒã®åœ¢æãåã³ä»ã®ã·ã°ãã«ååãšã®äŒåãç 究ãããããŠã¢ãã¿ãŒããããã«äœ¿çšããããšãã§ãããEP4-Gαã¿ã³ãã¯è³ªã®èåäœããã¢ãŽãã¹ãåã¯ã¢ã³ã¿ãŽãã¹ãã«å¿çããGã¿ã³ãã¯è³ªã«ããGTPã®çµååã³å æ°Žå解ã枬å®ããããã«äœ¿çšããããããŠåœæ¥è ã«ç¥ããããããã®æ¹æ³ã䜿çšããã¢ãŽãã¹ã掻æ§åã¯ã¢ã³ã¿ãŽãã¹ã掻æ§ã«é¢ããå°ååååç©ã©ã€ãã©ãªãŒã®ã¹ã¯ãªãŒãã³ã°ãåã³è©Šéšã«äœ¿çšãããããããã®äŸã¯ãåºç€åã³å¿çšç§åŠç 究ã«ãããŠæå¹ãªèåããŒãããŒåã³ãããã®äœ¿çšãæ瀺ããŠãããããã«éå®ããæå³ã¯ãªãã
ããã«EP4ã®çç©æŽ»æ§ã¯ã现èãé µæ¯ãäž¡çé¡è¥ããã¯åºä¹³é¡ã®å šäœã«ããã现è(äžèšã®çŽ°èããŒã¹ã¢ãã»ã€(cell-based assays)ãåç §ã®ããš)ã«ãŠãEP4ã¿ã³ãã¯è³ªãã倩ç¶ã¿ã³ãã¯è³ªåã¯èåã¿ã³ãã¯è³ªãšããŠçµã¿æãçºçŸããã(ããšãã°ãæäœãšãããŒãã»ã¿ã°ãç·è²èå ã¿ã³ãã¯è³ªãGαåã¯Î²-ã¢ã¬ã¹ãã³ã«æ¥åããEP4)åèšçŽ°èãçšããŠæž¬å®ããããšãã§ãããèåã¿ã³ãã¯è³ªã¯ã倩ç¶ã®ã¿ã³ãã¯è³ªãã幟ã€ãã®å©ç¹ããããå³ã¡èåã¿ã³ãã¯è³ªãã现èãçµç¹ãåã³çäœå ã®EP4ããªããããåã¯EP4ã®çç©æŽ»æ§ãçŽæ¥æ€åºã§ããããšãããŒã(FLAG,HA,polyHIS,c-mycç)ã¿ã°ä»ã(tagged)EP4ã¯ãå ç«ååŠæè²æ³ã«ãã现èåã³çµç¹å ã¿ã³ãã¯è³ªã®ãã©ããã³ã°ã«æå¹ã§ããããããŠå ç«èŠªåæ§ã¯ãããã°ã©ãã£ãŒãä»ãçŽç²ãåã¯å®è³ªçã«çŽç²ãªEP4ã¿ã³ãã¯è³ªã®åé¢ã®æ¯æŽãšãªãåŸããEP4ã¿ã³ãã¯è³ªã«èåãããç·è²èå ã¿ã³ãã¯è³ª(GFP)ã¯ãããšãã°çãã现èåã¯åºå®çŽ°èã«ãããŠä»ã®çŽ°èã¿ã³ãã¯è³ªãšã®åéåã¯äŒåããšã³ããµã€ãã·ãŒã¹å°èå ã§ã®å åšåã移å(trafficking)ãå解ãªã©ã®EP4ã¿ã³ãã¯è³ªã®äœçœ®ä»ãããããŠãã®ç§»åã®è¿œè·¡ã«äœ¿çšããããšãã§ãããGFPåã³èé žã®èåEP4ãããã€ããŒåã³ãªãªãŽããŒã®åœ¢æãåã³ä»ã®ã·ã°ãã«ååãšã®äŒåãç 究ãããããŠã¢ãã¿ãŒããããã«äœ¿çšããããšãã§ãããEP4-Gαã¿ã³ãã¯è³ªã®èåäœããã¢ãŽãã¹ãåã¯ã¢ã³ã¿ãŽãã¹ãã«å¿çããGã¿ã³ãã¯è³ªã«ããGTPã®çµååã³å æ°Žå解ã枬å®ããããã«äœ¿çšããããããŠåœæ¥è ã«ç¥ããããããã®æ¹æ³ã䜿çšããã¢ãŽãã¹ã掻æ§åã¯ã¢ã³ã¿ãŽãã¹ã掻æ§ã«é¢ããå°ååååç©ã©ã€ãã©ãªãŒã®ã¹ã¯ãªãŒãã³ã°ãåã³è©Šéšã«äœ¿çšãããããããã®äŸã¯ãåºç€åã³å¿çšç§åŠç 究ã«ãããŠæå¹ãªèåããŒãããŒåã³ãããã®äœ¿çšãæ瀺ããŠãããããã«éå®ããæå³ã¯ãªãã
EP4ã¿ã³ãã¯è³ªã®çç©æŽ»æ§ã調ç¯ãããããŠEP4ã¿ã³ãã¯è³ªã®çç©æŽ»æ§ã®å¢å€§åã¯æžå°ã«å¿çããŠãèªçºããããåã¯é»å®³ãããEP4éºäŒååã¯ãããã®éºäŒå矀ã®çºçŸã調ç¯ããååç©ã®åå®ã«çŽ°èããŒã¹ã¢ãã»ã€(cell-based assays)ãçšãããããåŸã£ãŠäžäŸã«ãããŠãEP4ã®çæå¯èœãªçŽ°èãã倩ç¶åã¯åæã®EP4ã¢ãŽãã¹ã/ã¢ã³ã¿ãŽãã¹ãã®ååšåã¯éååšäžã§è©Šéšååç©ãšå
±ã«ã€ã³ãã¥ããŒããããããŠãã®EP4ã®çç©æŽ»æ§ã枬å®ããããã®çµæã«ãã圢æãããEP4ã®çç©æŽ»æ§ã®å€åããè©Šéšååç©ãšæ¥è§ŠãããŠããªãã³ã³ãããŒã«EP4ç£ç现èãšæ¯èŒãããEP4çç©æŽ»æ§ã調ç¯ããæ¹ã«è©Šéšååç©ã®å¹èœã芪åæ§åã³äœçšãè©äŸ¡ããããã«ãããã®æž¬å®æ³ãçšããããã
æ²»çæ¹æ³
æ¬çºæã¯ãå°¿æåºã®æžå°åã³æ¥æ§åã¯æ ¢æ§ã®è é害ãšèšºæãããæ²»çæ£è ã®äºé²æ¹æ³ãšæ²»çæ¹æ³ãšã®äž¡æ¹ãæäŸãããå»ççãªçç¶åã³ãã®çºç ããé»å®³ãããããããã¯ãããããã®é²è¡ãé 延ãããããã«EP4ã®ç°åžžãç¹åŸŽä»ããçç¶ãæ瀺ãããåã«ãäºé²è¬ã®æäžãè¡ãªãããšãã§ãããäžè¬çã«ãäºé²æ¹æ³åã¯æ²»çæ¹æ³ã¯ãEP4ã¢ã³ã¿ãŽãã¹ãã®æå¹éãå¿ èŠãªå¯Ÿè±¡ç©ã«æ²»çãšããŠæäžããããšãå«ããæ¬çºæã«èšèŒãããŠããããã«ãé©åãªEP4ã¢ã³ã¿ãŽãã¹ãåã³ãã®èªå°äœã®äŸã¯ããããããããããæš¡å£ç©åã³å°ååæ¬äœãå«ããããã«éå®ãããªãã
æ¬çºæã¯ãå°¿æåºã®æžå°åã³æ¥æ§åã¯æ ¢æ§ã®è é害ãšèšºæãããæ²»çæ£è ã®äºé²æ¹æ³ãšæ²»çæ¹æ³ãšã®äž¡æ¹ãæäŸãããå»ççãªçç¶åã³ãã®çºç ããé»å®³ãããããããã¯ãããããã®é²è¡ãé 延ãããããã«EP4ã®ç°åžžãç¹åŸŽä»ããçç¶ãæ瀺ãããåã«ãäºé²è¬ã®æäžãè¡ãªãããšãã§ãããäžè¬çã«ãäºé²æ¹æ³åã¯æ²»çæ¹æ³ã¯ãEP4ã¢ã³ã¿ãŽãã¹ãã®æå¹éãå¿ èŠãªå¯Ÿè±¡ç©ã«æ²»çãšããŠæäžããããšãå«ããæ¬çºæã«èšèŒãããŠããããã«ãé©åãªEP4ã¢ã³ã¿ãŽãã¹ãåã³ãã®èªå°äœã®äŸã¯ããããããããããæš¡å£ç©åã³å°ååæ¬äœãå«ããããã«éå®ãããªãã
å°¿æåºã®æžå°ãè¡äžã®å°¿çªçŽ (BUN)åã³ã¯ã¬ã¢ããã³ã¬ãã«ã®å¢å€§ã«ããç¹åŸŽä»ããããããã®è
æ©èœäžè¯ã«ããçŸæ£ã®æ²»çãšããŠãæ¬çºæã®EP4ã¢ã³ã¿ãŽãã¹ãåã³ãã®èªå°äœã®çæ³çãªäœ¿çšãããä»ããããŒã¿ããè
çã®åç©ã¢ãã«ããåŸããããè
äžè¯ã«ããæ¥æ§è
çŸæ£ããèè¡ã«ããäºæ¬¡çãªè
çæµã®æ¬ ä¹ã«ãããåã¯æŸå°æ§ç·é 圱å€ãæè
«çæ§è¬ãæçç©è³ªãå
ç«é»å®³å€ãåã³ééå±ã«ããä»åšãããè
æ¯çŽ ã®çºäœã«ããèµ·ããå¯èœæ§ããããè
äžè¯ããäž¡åŽã®è
èåèã®éå¡(èè¡æ§è
ç)åã¯ã·ã¹ãã©ãã³ã®æ³šå
¥(æ¥æ§å°¿çŽ°ç®¡ã®å£æ»)ã«ããäœæããã2å¹ã®ã©ããã®ã¢ãã«ããããã®æ£è
ã眹ç
ããè
é害ãååã«ã«ç¹åŸŽä»ãããããŠãã®è
é害ãšè¿äŒŒããŠããããšãæ瀺ããŠãã(by Lieberthal,W.,Nigam,S.K.(2000);Am.J.Physiol.Renal.Physio.278(1):F1-F12ãåç
§)ãäž¡æ¹ã®ã©ããã®ã¢ãã«ãçšããããšã«ãããè
é害åã³è
èæ©èœã®æ¹è¯ã«æ¬çºæã®EP4ã¢ã³ã¿ãŽãã¹ãåã³ãã®èªå°äœã®æçšæ§ãæ瀺ãããã幟ã€ãã®äŸãæäŸããããã®ãã¡æ¬çºæã®EP4ã¢ã³ã¿ãŽãã¹ãåã³ãã®èªå°äœã䜿çšããããšã«ãããã©ãããããã¯ããã¿ã®ç³žçäœã®æ¿Ÿéãè
èã®è¡æµãåã³å°¿æåºã®æ¹è¯ãæ瀺ããããããã¯ãéã£ãçš®(ã©ãããããã¯ãåã³ãã¿)ã«ç€ºãããŠããããã«ãæ¬çºæã®EP4ã¢ã³ã¿ãŽãã¹ãã®è¬ççå¹èœããå容äœã®é
ååã³ãããã®çµç¹ãžã®åæ£ã«ãããé¡äŒŒæ§ã«åºã¥ããŠãããã®å¯Ÿè±¡ç©ãžããã«æ¡åŒµã§ããããšãäºæž¬ãããã
EP4ã¢ã³ã¿ãŽãã¹ãã®è¬ççãªèª¿è£œ
LD50(éå£ã®50%ãŸã§ã®èŽæ»æäžé)åã³ED50(éå£ã®50%ã®æ²»çæå¹æäžé)ãªã©ã®æ¬çºæã®EP4ã¢ã³ã¿ãŽãã¹ãã®æ¯æ§åã³æ²»çã®æå¹æ§ã¯ãå®éšåç©ã«ãããŠæšæºçãªå»è¬æ¹æ³ã«ãã決å®ããããšãã§ãããæ¯æ§ãšæ²»çå¹æãšã®æäžéæ¯ã¯ãæ²»çææ°ãšããŠç¥ããããããŠããããLD50/ED50æ¯ãšããŠè¡šãããšãã§ããã倧ããªæ²»çææ°ã瀺ãååç©ã奜ãŸãããããããååç©ã®æäžé(dosage)ã¯ãED50ãå«ããæ¯æ§ãã»ãšãã©å«ãŸãªãããå šãå«ãŸãªã埪ç°æ¿åºŠã®ç¯å²å ã§ããããšã奜ãŸããããã®æäžé(dosage)ã¯ãçšããããæäžé(dosage)ã®åœ¢åŒãåã³æäžçµè·¯ã«åºã¥ããŠãã®ç¯å²å ã«ãŠå€åããŠãããin vitroåã³ex vivoåææ³ãåã³åç©ã®ç 究ã«ãããŠæ±ºå®ããããããªIC50(ãã®çç¶ã®50%é»å®³ãéæããè©Šéšååç©ã®æ¿åºŠ)ãå«ã埪ç°è¡æŒ¿æ¿åºŠç¯å²ãåŸãããã®åç©ã®ã¢ãã«ã«ãããŠããã®æäžé(dose)ãåŠæ¹ããããšãã§ããã次ãã«ããããæ å ±ãçšããŠãããã«æå¹ãªæäžéãæ£ç¢ºã«æ±ºå®ããããšãã§ãããEP4ã¢ã³ã¿ãŽãã¹ãã®è¡æŒ¿ã¬ãã«ããããšãã°ã質éåå åæãšé£çµããé«é液äœã¯ãããã°ã©ãã£ãŒ(HPLC-MS)ã«ãã枬å®ããããšãã§ãããEP4ã¢ã³ã¿ãŽãã¹ãã®æå¹æäžéã¯ã0.01ÎŒgä¹è³100mg/kgã«ãŠå¯èœã§ããããŠæäžçµè·¯ãå»è¬ç©ã®èª¿è£œãåã³å°å ¥ã¢ãã«ã«ãã決å®ãããã
LD50(éå£ã®50%ãŸã§ã®èŽæ»æäžé)åã³ED50(éå£ã®50%ã®æ²»çæå¹æäžé)ãªã©ã®æ¬çºæã®EP4ã¢ã³ã¿ãŽãã¹ãã®æ¯æ§åã³æ²»çã®æå¹æ§ã¯ãå®éšåç©ã«ãããŠæšæºçãªå»è¬æ¹æ³ã«ãã決å®ããããšãã§ãããæ¯æ§ãšæ²»çå¹æãšã®æäžéæ¯ã¯ãæ²»çææ°ãšããŠç¥ããããããŠããããLD50/ED50æ¯ãšããŠè¡šãããšãã§ããã倧ããªæ²»çææ°ã瀺ãååç©ã奜ãŸãããããããååç©ã®æäžé(dosage)ã¯ãED50ãå«ããæ¯æ§ãã»ãšãã©å«ãŸãªãããå šãå«ãŸãªã埪ç°æ¿åºŠã®ç¯å²å ã§ããããšã奜ãŸããããã®æäžé(dosage)ã¯ãçšããããæäžé(dosage)ã®åœ¢åŒãåã³æäžçµè·¯ã«åºã¥ããŠãã®ç¯å²å ã«ãŠå€åããŠãããin vitroåã³ex vivoåææ³ãåã³åç©ã®ç 究ã«ãããŠæ±ºå®ããããããªIC50(ãã®çç¶ã®50%é»å®³ãéæããè©Šéšååç©ã®æ¿åºŠ)ãå«ã埪ç°è¡æŒ¿æ¿åºŠç¯å²ãåŸãããã®åç©ã®ã¢ãã«ã«ãããŠããã®æäžé(dose)ãåŠæ¹ããããšãã§ããã次ãã«ããããæ å ±ãçšããŠãããã«æå¹ãªæäžéãæ£ç¢ºã«æ±ºå®ããããšãã§ãããEP4ã¢ã³ã¿ãŽãã¹ãã®è¡æŒ¿ã¬ãã«ããããšãã°ã質éåå åæãšé£çµããé«é液äœã¯ãããã°ã©ãã£ãŒ(HPLC-MS)ã«ãã枬å®ããããšãã§ãããEP4ã¢ã³ã¿ãŽãã¹ãã®æå¹æäžéã¯ã0.01ÎŒgä¹è³100mg/kgã«ãŠå¯èœã§ããããŠæäžçµè·¯ãå»è¬ç©ã®èª¿è£œãåã³å°å ¥ã¢ãã«ã«ãã決å®ãããã
æ¬çºæã¯ã以äžã®ééå®è©Šæã«ããããã«è©³çŽ°ã«æ瀺ãããã
ããããã®ååŠåæ
213.15(é åçªå·1)ã®æ§é ã«åºã¥ã幟ã€ãã®ããããããF-mocååŠåã³åºçžã¡ãªãã£ã«ã(Merrifield)ããããæ³ãçšããŠåæããããããããããã®æ§é ã¯ãè¡š3(é åçªå·2ä¹è³13)ã«1芧ãšããŠèšèŒãããŠããããããããããé¡ã®ããªãã«ãªãé ¢é žå¡©ã®çŽåºŠããHPLCãšè³ªéåæã«ãŠåæãããäžè¬çåææ³ã¯ã以äžã®æç®(ãåºçžããããåæãStewart & Young,W.H.Freeman Co.San Francisco,1969;ãã¿ã³ãã¯è³ªã,Erikson and Merrifield,Vol.2.(ed.Neurath & Hill))ã«èšåããããšã«ããååã«ç解ãããã§ããããããã«æ°Žãžã®ãããã溶解床ããäžèŠ§ãšããŠè¡š3ã«èšèŒããã
213.15(é åçªå·1)ã®æ§é ã«åºã¥ã幟ã€ãã®ããããããF-mocååŠåã³åºçžã¡ãªãã£ã«ã(Merrifield)ããããæ³ãçšããŠåæããããããããããã®æ§é ã¯ãè¡š3(é åçªå·2ä¹è³13)ã«1芧ãšããŠèšèŒãããŠããããããããããé¡ã®ããªãã«ãªãé ¢é žå¡©ã®çŽåºŠããHPLCãšè³ªéåæã«ãŠåæãããäžè¬çåææ³ã¯ã以äžã®æç®(ãåºçžããããåæãStewart & Young,W.H.Freeman Co.San Francisco,1969;ãã¿ã³ãã¯è³ªã,Erikson and Merrifield,Vol.2.(ed.Neurath & Hill))ã«èšåããããšã«ããååã«ç解ãããã§ããããããã«æ°Žãžã®ãããã溶解床ããäžèŠ§ãšããŠè¡š3ã«èšèŒããã
èè¡æ§è
çã®ã©ããã®ã¢ãã«ã®ç³žçäœæ¿Ÿéåã³å°¿æåºã«åãŒã213.15ã®èªå°äœã®å¹æ
äž¡åŽã®è èåèã30ä¹è³60åéåºå®ããããšã«ããè èã®åæœ æµãšãªãããããŠç³žçäœã®æ¿Ÿéçã®åçãªæžå°ãå°¿ã®æåºãåã³ç®¡çŽ°èã®æ»ãªã©ã®é¢é£ããäœåŸçŸæ£ãçããããã®ã¢ãã«ã¯ãããã®æ¬ ä¹å°¿è äžå šãšããç¹å®ã®é倧ãªçµæãåçŸãããè æå·ã®åŸ©åž°ã«ãããçš®ã ã®213.15èªå°äœã®å¹èœã枬å®ãããã
äž¡åŽã®è èåèã30ä¹è³60åéåºå®ããããšã«ããè èã®åæœ æµãšãªãããããŠç³žçäœã®æ¿Ÿéçã®åçãªæžå°ãå°¿ã®æåºãåã³ç®¡çŽ°èã®æ»ãªã©ã®é¢é£ããäœåŸçŸæ£ãçããããã®ã¢ãã«ã¯ãããã®æ¬ ä¹å°¿è äžå šãšããç¹å®ã®é倧ãªçµæãåçŸãããè æå·ã®åŸ©åž°ã«ãããçš®ã ã®213.15èªå°äœã®å¹èœã枬å®ãããã
èè¡æ§è
çã®ã¢ãã«
ã¹ãã¬ã€ã°ã»ããŠã¬ã€ã»ã©ãã(Sprague-Dawley rats(250-300g))ã«éº»é ãããããããŠé éèã«ã«ãã¥ãŒã¬ãæ¿å ¥ããããããåã¯ççé£å¡©æ°Žãæ³šå ¥ãããããã«å ãé åèã«ã«ãã¥ãŒã¬ãæ¿å ¥ããå§å€æåš(Gould)ã«ãŠåèã®è¡å§æž¬å®ãããããŠè¡æ¶²è©Šæãæ¡éãããèè±ã«ã«ãã¥ãŒã¬ãæ¿å ¥ãå°¿ãæ¡åãããå°å°¿ç®¡ã®æ¿å ¥ã®åŸã[3H]ã€ã³ã¹ãªã³(8ÎŒCi/hr),[14C]ã¢ããéŠ¬å°¿é ž(0.8ÎŒCi/hr)åã³éº»é è¬(ã±ã¿ãã³ãšãã©ãžã³(Ketamine and xylazine),9:1 w:w;0.095ml/ml)æ··å液ã®æ³šå ¥(1.6ml/hr)ãéå§ãããããã«ãã®åç©ã40åéã«ãŠå®å®åãããã2åã®å°¿è©Šæãã10åéã«ããã£ãŠæ¡å(40ãã50åããš50ãã60å)ããåºæ¬GFRã®å®å®æ§ãè©äŸ¡ããã45åãš55åã«ãŠè¡æ¶²è©Šæã®ãããããæ¡åããã次ãã«å·Šå³ã®è åèã®éåæ¢ã(clamped)ã60åéè¡ããæ¥æ§èè¡æ§è çç¶ãèªçºããããèçµçç¶ã®æéåŸãã®åç©ãããããã,213.19-213.30,(ããŠã©ã¹(bolus)ã®1mg/kgã®é泚)ãåã¯é éèãä»ããççé£å¡©æ°Žã«ãŠåŠçããã次ãã«è¡æ¶²åã³å°¿è©Šæããããã«2æéã®éã«20åæ¯ã«æ¡åããã糞çäœæ¿Ÿéé床(GFR)åã³å°¿æµéç床([3H]ããã¯ãªã³æ³ã«ãŠæž¬å®)ãåã³è è¡æŒ¿æµé([14C]ã¢ããéŠ¬å°¿é žæ³ã«ãŠæž¬å®)ããç°ãªãæéã«ãŠããããŠ60åéãå¹³åããŠ(è¬å€æäžããŠ20-30ååŸ)決å®ããã
ã¹ãã¬ã€ã°ã»ããŠã¬ã€ã»ã©ãã(Sprague-Dawley rats(250-300g))ã«éº»é ãããããããŠé éèã«ã«ãã¥ãŒã¬ãæ¿å ¥ããããããåã¯ççé£å¡©æ°Žãæ³šå ¥ãããããã«å ãé åèã«ã«ãã¥ãŒã¬ãæ¿å ¥ããå§å€æåš(Gould)ã«ãŠåèã®è¡å§æž¬å®ãããããŠè¡æ¶²è©Šæãæ¡éãããèè±ã«ã«ãã¥ãŒã¬ãæ¿å ¥ãå°¿ãæ¡åãããå°å°¿ç®¡ã®æ¿å ¥ã®åŸã[3H]ã€ã³ã¹ãªã³(8ÎŒCi/hr),[14C]ã¢ããéŠ¬å°¿é ž(0.8ÎŒCi/hr)åã³éº»é è¬(ã±ã¿ãã³ãšãã©ãžã³(Ketamine and xylazine),9:1 w:w;0.095ml/ml)æ··å液ã®æ³šå ¥(1.6ml/hr)ãéå§ãããããã«ãã®åç©ã40åéã«ãŠå®å®åãããã2åã®å°¿è©Šæãã10åéã«ããã£ãŠæ¡å(40ãã50åããš50ãã60å)ããåºæ¬GFRã®å®å®æ§ãè©äŸ¡ããã45åãš55åã«ãŠè¡æ¶²è©Šæã®ãããããæ¡åããã次ãã«å·Šå³ã®è åèã®éåæ¢ã(clamped)ã60åéè¡ããæ¥æ§èè¡æ§è çç¶ãèªçºããããèçµçç¶ã®æéåŸãã®åç©ãããããã,213.19-213.30,(ããŠã©ã¹(bolus)ã®1mg/kgã®é泚)ãåã¯é éèãä»ããççé£å¡©æ°Žã«ãŠåŠçããã次ãã«è¡æ¶²åã³å°¿è©Šæããããã«2æéã®éã«20åæ¯ã«æ¡åããã糞çäœæ¿Ÿéé床(GFR)åã³å°¿æµéç床([3H]ããã¯ãªã³æ³ã«ãŠæž¬å®)ãåã³è è¡æŒ¿æµé([14C]ã¢ããéŠ¬å°¿é žæ³ã«ãŠæž¬å®)ããç°ãªãæéã«ãŠããããŠ60åéãå¹³åããŠ(è¬å€æäžããŠ20-30ååŸ)決å®ããã
è¡šïŒïŒ213.15ã®æ§é ã«åºã¥ãåæãããããããã©ã€ãã©ãªãŒ
ΟïŒå€§æåã¯L-ã¢ããé
žã瀺ããå°æåã¯ãD-ã¢ããé
žã瀺ãïŒbip:D-(4,4)ããã§ãã«ã¢ã©ãã³ïŒBipïŒL-(4,4)ããã§ãã«ã¢ã©ãã³
*ïŒæº¶è§£æ§ãæ°Žäžã«ãŠæ±ºå®ãããã
*ïŒæº¶è§£æ§ãæ°Žäžã«ãŠæ±ºå®ãããã
å°¿ã®æµéç床(å³1A)åã³GFR(å³1B)ã«é¢ããçµæã¯ãè¬å€ã®æäžãã20ååŸããéå§ãã60åã«ãããå°¿ã®å¹³åæµéç床åã³å¹³åGFRãšããŠè¡šããããå°¿æåºã®å¹èœé äœãã213.15<213.19â§213.21ã§ãããä»ã®ããããã213.15ãšåæ§ã®å¹èœããã£ããããã«ãåãããã«213.19åã³213.21ã¯ãGFRã®å¢å€§ã瀺ãããGFRã®æ¹è¯ããä»ã®ããããã«å¯ŸããŠèŠ³å¯ãããªãã£ããGFRãå°¿ã®æµéç床åã³è
è¡æŒ¿ã®æµéçã®æ¹è¯ã«ã¯ããããã213.19åã³213.21ããäžè²«ããŠä»ã®ããããããåªããŠããã
213.21ã®æ§é ã«åºã¥ããŠãããé¡äŒŒãã4çš®ã®213.27ä¹è³213.30ããè
èåèã®éå¡ã®ã©ããã®ã¢ãã«ã«ãããŠåæãããããŠè©ŠéšããããGFRã®çµæ(60åéã®å¹³åãšè¬å€ã®æ³šå
¥ãã20ååŸã®éå§)ããå³ïŒCã«ç€ºããæ¯èŒã®ãã213.15åã³213.21ããã®å³ã«èšèŒããããã¡ãã213.28ãš213.29ãå
±ã«ã40åéã«è
èåèã®éåæ¢ããå€ããåŸ40åéã«ãããã察ç
§ãšãã213ã»15ãšæ¯èŒãïŒåãšïŒåã®GFRãå¢å€§ãããããã«è©Šéšååç©ã®ãã¡ææã«æº¶è§£å¯èœãª(è¡šïŒïŒ213.28ãš213.29ã¯ã芪ååç©ã®213.15ããææã«æå¹ã§ããããšãèŠåºãããã
æ£åžžãªã©ãããããã¯åã³ä»ãã¿ã®è
èæ©èœã«åãŒã213.29ã®æäž(dose)å¿ç
213.29(1,2,3,4,5,10mg/kg ããŒã©ã¹é泚(bolus iv))ã®æäžå¿çãã麻é ã«ããããéã®ããŒã°ã«ã»ããã¯ã«ãŠè©Šéšããããå°ãªããšã1é±éã®éŠŽåãš1æŒå€ã®çµ¶é£ã®åŸãããããã®åç©ããããªãã³ã¿ãŒã«(5mg/kg)ã«ããéè泚å°ã«ãŠéº»é ã«ããããã®éº»é ãã€ãœãã«ã©ã³äžã«ãŠæç¶ããããã®åç©ãä¿æž©ãããããŠãã®äœå 枩床ã15åæ¯ã«ã¢ãã¿ãŒãããè¡å§ãã¢ãã¿ãŒããé åèã«ããŒãã«ãåã³å°¿ãæ¡åããå°å°¿ç®¡ãåãä»ããã5æéã®å°å ¥ãšããŠååãªå šæäžé0.05mCiã®[3H]ã®ããã¯ãªã³åã³0.005mCiã®[14C]ãã©ã¢ããéŠ¬å°¿é ž(PAH)ãå«ããççé£å¡©æ°Ž(10mL/kg/h)ã®é泚ã«ããäžå®éã®æ³šå ¥ãéå§ãããè©ŠæãšããŠã®å°¿ã10åæ¯ã«æ¡åãããå10åéã®äžéç¹ã«ãŠè¡æ¶²è©Šæãæ¡åãããæŸå°æ§æšèã«ãã60åéã®å¹³è¡¡åã®åŸãé次å¢å (incremental)ã«ãã213.29ã®æäžé(doses)ããé éšéèãçµç±ããŠéèå ã«æ³šå ¥ãããã
213.29(1,2,3,4,5,10mg/kg ããŒã©ã¹é泚(bolus iv))ã®æäžå¿çãã麻é ã«ããããéã®ããŒã°ã«ã»ããã¯ã«ãŠè©Šéšããããå°ãªããšã1é±éã®éŠŽåãš1æŒå€ã®çµ¶é£ã®åŸãããããã®åç©ããããªãã³ã¿ãŒã«(5mg/kg)ã«ããéè泚å°ã«ãŠéº»é ã«ããããã®éº»é ãã€ãœãã«ã©ã³äžã«ãŠæç¶ããããã®åç©ãä¿æž©ãããããŠãã®äœå 枩床ã15åæ¯ã«ã¢ãã¿ãŒãããè¡å§ãã¢ãã¿ãŒããé åèã«ããŒãã«ãåã³å°¿ãæ¡åããå°å°¿ç®¡ãåãä»ããã5æéã®å°å ¥ãšããŠååãªå šæäžé0.05mCiã®[3H]ã®ããã¯ãªã³åã³0.005mCiã®[14C]ãã©ã¢ããéŠ¬å°¿é ž(PAH)ãå«ããççé£å¡©æ°Ž(10mL/kg/h)ã®é泚ã«ããäžå®éã®æ³šå ¥ãéå§ãããè©ŠæãšããŠã®å°¿ã10åæ¯ã«æ¡åãããå10åéã®äžéç¹ã«ãŠè¡æ¶²è©Šæãæ¡åãããæŸå°æ§æšèã«ãã60åéã®å¹³è¡¡åã®åŸãé次å¢å (incremental)ã«ãã213.29ã®æäžé(doses)ããé éšéèãçµç±ããŠéèå ã«æ³šå ¥ãããã
è¡æ¶²è©Šæåã³å°¿è©Šæ(n=30/dog)äžã®æŸå°èœããã·ã³ãã¬ãŒã·ã§ã³åå
åšã«ãŠæ±ºå®ãããç 究ã®çµæãå³ïŒAã«ç€ºãããGFRåã³å°¿ã®æµåé床ã§ã¯ãåçã«ããã«æ倧ã®å¢å€§ããæ£åžžãªããã¯ã®4mg/kgã®213.29ã«ãŠèŠ³å¯ããããããã«å³2Bã¯ãã©ããåã³ä»ãã¿ã«ãŠè¡ãªãããåæ§ã®ç 究çµæã瀺ããŠãããGFRãå°¿ã®æµéçåã³è
è¡æŒ¿ã®æµéçã«ãããæ倧å¿çã芳å¯ãããæäžéããå³ïŒBã®æ¿å
¥å³ã«ç€ºã(n=åç©ã®æ°)ããã®çµæã«ãã瀺ãããããšã¯ã213.29ã¯ãçš®ãšã¯ç¡é¢ä¿ãªæ§åŒã§è
èãžã®æœ
æµã®å¢å€§ãGFRã®å¢å€§ãåã³å°¿æåºã®å¢å€§ãåŒãèµ·ããããšã§ããããããã®çµæã¯ã瀺åã«ããã°ã213.29ããããã«ãããè
çæµãGFRåã³å°¿ã®æµéã®å¢å€§ã«æå¹ã§ããããšã瀺åããŠããã
PGE2ã«ãŠèªçºããããã¿ã®äœéšäŒåšéèãªã³ã°ã®æ¡åŒµã«åãŒã213.29ã®å¹æ
åç©
Animal Care Committee of the Research Center of the St.-Justine Hospitalã«ãŠåãå ¥ãããæ¹æ³ã«ããããšãŒã¯ã·ã£çš®(Yorkshhire)ã®ä»ãã¿(2ä¹è³4æ¥çµé)ãããã®ç 究ã«çšãããããç°¡åã«ãããšãåç©ãããã¿ã³(1.5%))ã«ãŠéº»é ã«ããããããŠåºéšã®å€éšäŒåšã®éèãåãåºãã以äžã®çµæç©ãæããããªãã¡NaCl 120,KCl 4.5,CaCl 2.5,MgSO4 1.0,NaHCO3 27,KH2PO4 1.0,ã°ã«ã³ãŒã¹ 10ãå«ã¿ãããã«1.5U/mlã®ãããªã³ãæ·»å ããçµæç©(mM)ãæããå·åŽããã¯ã¬ãã¹ã»ç·©è¡æ¶²(Krebs buffer)(pH7.4)å ã®æå®ã®äœçœ®ã«çœ®ããã
åç©
Animal Care Committee of the Research Center of the St.-Justine Hospitalã«ãŠåãå ¥ãããæ¹æ³ã«ããããšãŒã¯ã·ã£çš®(Yorkshhire)ã®ä»ãã¿(2ä¹è³4æ¥çµé)ãããã®ç 究ã«çšãããããç°¡åã«ãããšãåç©ãããã¿ã³(1.5%))ã«ãŠéº»é ã«ããããããŠåºéšã®å€éšäŒåšã®éèãåãåºãã以äžã®çµæç©ãæããããªãã¡NaCl 120,KCl 4.5,CaCl 2.5,MgSO4 1.0,NaHCO3 27,KH2PO4 1.0,ã°ã«ã³ãŒã¹ 10ãå«ã¿ãããã«1.5U/mlã®ãããªã³ãæ·»å ããçµæç©(mM)ãæããå·åŽããã¯ã¬ãã¹ã»ç·©è¡æ¶²(Krebs buffer)(pH7.4)å ã®æå®ã®äœçœ®ã«çœ®ããã
åšå®æ§œã¢ãã»ã€
äŒåšéèããå€ççµç¹ããæž æµã«ãã4mmã®ãªã³ã°ã«åæãããããKrebsç·©è¡æ¶²ãå«ãåã ã«è¢«èŠããã(jackted)åšå®æ§œ(15ml;Radnoti Glass,Monrovia,CA)ã«çœ®ããŠãããã«37âã«ç¶æããããã®æº¶æ¶²ããO2/CO2ã®æ··åã¬ã¹(95/5)ã«ãŠæ³¡ç«ããããåå®éšã«8åã®ãªã³ã°ã䜿çšã(åäŒåšéèããïŒã€)ããããŠé »ç¹ãªæŽæµã«äŒŽã2.0grã®åå匵å(passive tension)ãåã³ãã®åŒµåã®èª¿æŽäžã«ãŠ60åé平衡ç¶æ ã«ããããã®åŒµåãã匵åå€äœè»¢æè£ çœ®ã«ãã枬å®ããWork BenchãœãããŠãšã¢(Kent Scientific,Litchfield,CTããå ±ã«)ãçšããŠãèšç®ããŒã¿ç²åŸã·ã¹ãã ã«ãŠèšé²ããã
äŒåšéèããå€ççµç¹ããæž æµã«ãã4mmã®ãªã³ã°ã«åæãããããKrebsç·©è¡æ¶²ãå«ãåã ã«è¢«èŠããã(jackted)åšå®æ§œ(15ml;Radnoti Glass,Monrovia,CA)ã«çœ®ããŠãããã«37âã«ç¶æããããã®æº¶æ¶²ããO2/CO2ã®æ··åã¬ã¹(95/5)ã«ãŠæ³¡ç«ããããåå®éšã«8åã®ãªã³ã°ã䜿çšã(åäŒåšéèããïŒã€)ããããŠé »ç¹ãªæŽæµã«äŒŽã2.0grã®åå匵å(passive tension)ãåã³ãã®åŒµåã®èª¿æŽäžã«ãŠ60åé平衡ç¶æ ã«ããããã®åŒµåãã匵åå€äœè»¢æè£ çœ®ã«ãã枬å®ããWork BenchãœãããŠãšã¢(Kent Scientific,Litchfield,CTããå ±ã«)ãçšããŠãèšç®ããŒã¿ç²åŸã·ã¹ãã ã«ãŠèšé²ããã
å®éšæ¹æ³
PGE2ã«å¯Ÿããäœéšå€æ§äŒåšéèã®è¡ç®¡æ¡åŒµå¿çããEP2(30%)ãšEP4(70%)ã®åºæ¿ããã®çµæãšèŠåããããããã®çµç¹ãã1.5ä¹è³2.0grã®åŒµåã®å¢å€§ãèªçºããU46619(2x10-7M)(ããã³ãããµã³A2æ¬äœ)ã«ãããæåã«ãã£ã¬ã³ãžããããå¿çã®ãªããªã³ã°ãå»æ£ãããU46619ãžã®å¿çãå®åžžç¶æ ã«éããæã«è¬å€ãæ·»å ãããè¬å€ã«å¯Ÿããå¿çã芳å¯ãããªãæã30åéã«ãŠãçµç¹å ã«è¬å€ã®é©åãªåæ£ã確å®ãªãã®ãšããã次ãã«PGE2(10-10-10-6M)ãžã®æäžéå¿çæ²ç·ããåè©Šéšè¬å€ã®ååšåã¯éååšäžã«ãŠåŸãããã
PGE2ã«å¯Ÿããäœéšå€æ§äŒåšéèã®è¡ç®¡æ¡åŒµå¿çããEP2(30%)ãšEP4(70%)ã®åºæ¿ããã®çµæãšèŠåããããããã®çµç¹ãã1.5ä¹è³2.0grã®åŒµåã®å¢å€§ãèªçºããU46619(2x10-7M)(ããã³ãããµã³A2æ¬äœ)ã«ãããæåã«ãã£ã¬ã³ãžããããå¿çã®ãªããªã³ã°ãå»æ£ãããU46619ãžã®å¿çãå®åžžç¶æ ã«éããæã«è¬å€ãæ·»å ãããè¬å€ã«å¯Ÿããå¿çã芳å¯ãããªãæã30åéã«ãŠãçµç¹å ã«è¬å€ã®é©åãªåæ£ã確å®ãªãã®ãšããã次ãã«PGE2(10-10-10-6M)ãžã®æäžéå¿çæ²ç·ããåè©Šéšè¬å€ã®ååšåã¯éååšäžã«ãŠåŸãããã
2ä¹è³8ã®å®éšã®å¹³åããçµæãå³3ã«ç€ºãããã®çµæã¯ãä»ãã¿ã«ã1ÎŒMã®ããããã®ååšäžã§1ÎŒMã®U46619(ããã³ãããµã³A2æ¬äœ)ãšäºãæ¥è§Šãããä»ãã¿ã®äœéšäŒåšéèãªã³ã°ã«ãããŠã1ÎŒMã®PGE2ã«ããçæãããæ¡åŒµã®é転ã®æ¯ç(percent reversal)ãšããŠè¡šãããã213.29ã¯ããã®çµç¹å
ã®PGE2ã«ãããæ¡åŒµå¹æã®çŽ50%é転ãããã
ããè¡æž
ã«ããã213.29ã®å®å®æ§ãåã³ä»£è¬ãšããŠã®çç©æŽ»æ§
213.29ããããããè¡æž ãããã¢ãŒãŒã掻æ§ã«ãããšèããããL-ã¢ããé žãå«ãã213.29ã®å€æ§çæç©ãç¹åŸŽä»ããããã®çåé(aliquots)(100ÎŒg)ããããã®è¡æž äžã«ãŠæéãå€ããŠã37âã«ãŠã€ã³ãã¥ããŒãããããã®åå¿ç©ãããªãã«ãªãé ¢é ž(0.24ml;1M)ã«ãŠæ¥å·ãã10åéæ°·äžã«ãŠã€ã³ãã¥ããŒãããããã«ãã®åŸTFA(0.25ml;0.05%)ãæ·»å ãããããŠé å¿åé¢ã«ãããŠçŸæ¯å¡ç¶ç©ãæ²æ®¿ããããäžæž ç©ãSepPak C18ã«ãŒããªããžäžã§åºçžæœåºã«ãã粟補ããã0.05%ã®TFAäžã§ãã®ãããããã80%ã®ã¢ã»ããããªã«ã«ãŠåžéãã溶é¢ç©ãåçµä¹Ÿç¥ããã次ãã«ãã®ãããããé ¢é ž(0.1Nã«ãŠ400ÎŒl)ã§å溶解ããéçžHPLCã®C18ã«ã©ã äžã«ãŠåé¢ãããç»åãå«ãããŒã¯ç©è³ªãæ¡éããããããæçã®è³ªéãMALDI-TOFã«ãŠæ±ºå®ããã
213.29ããããããè¡æž ãããã¢ãŒãŒã掻æ§ã«ãããšèããããL-ã¢ããé žãå«ãã213.29ã®å€æ§çæç©ãç¹åŸŽä»ããããã®çåé(aliquots)(100ÎŒg)ããããã®è¡æž äžã«ãŠæéãå€ããŠã37âã«ãŠã€ã³ãã¥ããŒãããããã®åå¿ç©ãããªãã«ãªãé ¢é ž(0.24ml;1M)ã«ãŠæ¥å·ãã10åéæ°·äžã«ãŠã€ã³ãã¥ããŒãããããã«ãã®åŸTFA(0.25ml;0.05%)ãæ·»å ãããããŠé å¿åé¢ã«ãããŠçŸæ¯å¡ç¶ç©ãæ²æ®¿ããããäžæž ç©ãSepPak C18ã«ãŒããªããžäžã§åºçžæœåºã«ãã粟補ããã0.05%ã®TFAäžã§ãã®ãããããã80%ã®ã¢ã»ããããªã«ã«ãŠåžéãã溶é¢ç©ãåçµä¹Ÿç¥ããã次ãã«ãã®ãããããé ¢é ž(0.1Nã«ãŠ400ÎŒl)ã§å溶解ããéçžHPLCã®C18ã«ã©ã äžã«ãŠåé¢ãããç»åãå«ãããŒã¯ç©è³ªãæ¡éããããããæçã®è³ªéãMALDI-TOFã«ãŠæ±ºå®ããã
å³4Aã¯ãçµéæéã«å¯Ÿãã213.29ã®å€æ§ãåã³1ã®ã«ã«ããã·æ«ç«¯ã®ãªã·ã³(213.291)(å³4B)æ¬ æã«ããã1ã®ä»£è¬çæç©ã®åºçŸã瀺ããåæãè¿
éã§2åããçãåæžæã䌎ãã第äºã®ä»£è¬ç£ç©ãšããŠã®213,292(å³4B)ããæ¬å®éšã«èŠ³å¯ãããªãããããŠå解åå¿ã«ãããŠçŸããã®ãé
ãã
ããã«ä»£è¬ç£ç©ããçç©æŽ»æ§ãæãããã©ããè©Šéšããããã®ãããã213.29ã213.292ãåã³213.292ãã100nMã®PGE2ã®ååšäžã«ãŠããEP4ãªã»ãã¿ãŒãçµã¿æãçºçŸããHEK293现èãšå
±ã«ã€ã³ãã¥ããŒããããcAMPã®ã¬ãã«ãæŸå°æ§å
ç«æ³ã«ãŠæ±ºå®ãããããŠãã®çµæãå³4Bã«ç€ºãããããèªèº«ã®ããããã¯ãå容äœã®åºæ¿ãæ¹èµ·ããªãããPGE2ã«ãŠåºæ¿ãããcAMPã®åæã20-30%ã ãé»å®³ããã
213.29ããä»ã®ããã¹ã¿ãã€ãå容äœã®çç©çå¿çã«åœ±é¿ããªãããšãå®èšŒãããããããã¹ã¿ãã€ãå容äœã®éžæçãªã¬ã³ã(ãã¿ããã¹ã-EP2;17-ãã§ãã«PGE2-EP1;PGF2a-FP;U46619-TP;M&B28767-EP3)ããäºãèšèŒãããããŠæ€èšŒããããã¿ã®ç¶²è(Li,D.Y.,Abran,D.,Peri,K.G.,Varma,D.R.,Chemtob,S.(1996);J.Pharmacol.Exp.Ther.278(1):370-7)ã®ex vivoã«ãããè¡ç®¡ççªåææ³ã«äœ¿çšãããååš©æååŸã®é«åŸªç°ã¬ãã«ã®ããã¹ã¿ã°ã©ã³ãžã³ãäžé調ç¯ããããšã«ãã£ãŠãæ°çè¡ç®¡ç³»ã®ããã¹ã¿ãã€ãå容äœã®å¯åºŠããæå°ãšãªãããšãããæ°çãã¿ããããã¹ã¿ã°ã©ã³ãžã³åæé
µçŽ ã®é®æå€ã®ã€ããããã§ã³((ibuprofen)(30mg/kg(äœéã®)/8æéä¹è³24æé))ã«ãŠåŠçããå容äœã®å¯åºŠåã³è¡ç®¡éåå¹æãå¢å€§ãããã
æ¹æ³
çŒæ¯ã調補ããããã«ãéžç¶çž(ora serrata)ãã3ä¹è³4mmåŸéšã«å圢ç¶ã®åéãè¡ãªããã網èã®åãæ±ããæå°éã«ãå éšç¯åã³ç¡åäœãåãåºãããçãŸã£ãŠããçŒæ¯ãã20mlã®Kreb'sã®ç·©è¡æ¶²(pH 7.35ä¹è³7.45)ãå«ã20mlã®çµç¹æµŽæ§œäžã§ã¯ãã¯ã¹ã»ããŒã¹ã«åãããã³ã«ãŠåºå®ãããããŠ21%ã®é žçŽ ãš5%ã®äºé žåççŽ ã«ãŠã37âã§å¹³è¡¡åããããã®èª¿è£œç©ã30åéã«ãŠå®å®åããã
çŒæ¯ã調補ããããã«ãéžç¶çž(ora serrata)ãã3ä¹è³4mmåŸéšã«å圢ç¶ã®åéãè¡ãªããã網èã®åãæ±ããæå°éã«ãå éšç¯åã³ç¡åäœãåãåºãããçãŸã£ãŠããçŒæ¯ãã20mlã®Kreb'sã®ç·©è¡æ¶²(pH 7.35ä¹è³7.45)ãå«ã20mlã®çµç¹æµŽæ§œäžã§ã¯ãã¯ã¹ã»ããŒã¹ã«åãããã³ã«ãŠåºå®ãããããŠ21%ã®é žçŽ ãš5%ã®äºé žåççŽ ã«ãŠã37âã§å¹³è¡¡åããããã®èª¿è£œç©ã30åéã«ãŠå®å®åããã
0.1ÎŒMã®ãªã¬ã³ããã济槜液äžã«æ·»å ãããåã«213.29(10ÎŒM)ãã5åéã«ãããæ·»å ãããè管ã®å€åŸ(outer vessel diameter)ããå®äœé¡åŸ®é¡(dissecting microscope(Zeiss M 400)äžã«åãä»ãããããããªã»ã«ã¡ã©ã«èšé²ãããããŠãã®å¿çãããžã¿ã«ç»å解æè£
眮(Sigma Scan Software,Jandel Scientific,Corte Madera,CA)ã«ãŠå®éåãããã¢ãŽãã¹ããå±æé©å¿ããååã³é©å¿ãã5ååŸã«ããã®è¡ç®¡ã®çŽåŸãèšé²ããã枬å®ããããã3åç¹°ãè¿ããããããŠ1%ããäœãå€åã瀺ããããå³5ã«ç€ºãããã«ã213.29ã¯ãããã¹ã¿ãã€ãå容äœã®å容äœéžæã¢ãŽãã¹ãã®åçž®å¿çåã¯æ¡åŒµå¿çã«åœ±é¿ãäžããªãã£ããåŸã£ãŠ213.29ã¯ãããã¹ã¿ãã€ãå容äœEP4ã«é«ãéžææ§ããããšèããããã
èè¡æ§è
çã®ã©ããã®ã¢ãã«ã®è
æ©èœã®æ¹è¯ã«ããããã§ãã«ããã (0)ãš213.29ãšã®æ¯èŒ
ãã§ãã«ããã (Fenoldopam)ã¯ããããŒãã³å容äœã®ãµãã¿ã€ãã®1ã¢ãŽãã¹ãã§ããããããŠéå®ããããèšåºçã«åã³åç©å®éšã«ãããŠå°¿æåºã®å¢å€§ã瀺ãã(Singer,I.and Epstein,M.1998;Am.J.Kidney Dis.31(5):743-55)ãèè¡æ§è çã®ã©ããã®ã¢ãã«ã®è æ©èœã®æ¹è¯ã«ããããã§ãã«ããã (Fenoldopam)ãš213.29ãšã®å¹èœ(å®æœäŸ2ã«èšèŒ)ãæ¯èŒããã213.29ãé泚ããŒã©ã¹ã§1mg/kgäžããäžæ¹ãã§ãã«ããã (Fenoldopam)ãé泚ããŒã©ã¹ã§0.6ÎŒg/kgãç¶ããŠ0.6ÎŒg/kg/hå®éšæéäžã«äžãããå³6Aã«ç€ºãããã«ããã§ãã«ããã (Fenoldopam)ãš213.29ãå ±ã«åçšåºŠã®å°¿æåºãå¢å€§ãããã°ãããã213.29ã¯ãè æ©èœãšããŠã®æœ æµãåã³GFRãææã«æ¹è¯ããããšãã§ãããè¡æ¶²å°¿çŽ çªçŽ (BUN)åã³è¡æž ã®ã¯ã¬ã¢ããã³ã»ã¬ãã«ãã72æéåŸã«æž¬å®ãããããŠå³6Bã«ç€ºãããã«ãã§ãã«ããã (Fenoldopam)ãš213.29ãå ±ã«ãBUNåã³ã¯ã¬ã¢ããã³ã»ã¬ãã«ã®æžå°ã«ãããå¹æãåãã§ãã£ãã
ãã§ãã«ããã (Fenoldopam)ã¯ããããŒãã³å容äœã®ãµãã¿ã€ãã®1ã¢ãŽãã¹ãã§ããããããŠéå®ããããèšåºçã«åã³åç©å®éšã«ãããŠå°¿æåºã®å¢å€§ã瀺ãã(Singer,I.and Epstein,M.1998;Am.J.Kidney Dis.31(5):743-55)ãèè¡æ§è çã®ã©ããã®ã¢ãã«ã®è æ©èœã®æ¹è¯ã«ããããã§ãã«ããã (Fenoldopam)ãš213.29ãšã®å¹èœ(å®æœäŸ2ã«èšèŒ)ãæ¯èŒããã213.29ãé泚ããŒã©ã¹ã§1mg/kgäžããäžæ¹ãã§ãã«ããã (Fenoldopam)ãé泚ããŒã©ã¹ã§0.6ÎŒg/kgãç¶ããŠ0.6ÎŒg/kg/hå®éšæéäžã«äžãããå³6Aã«ç€ºãããã«ããã§ãã«ããã (Fenoldopam)ãš213.29ãå ±ã«åçšåºŠã®å°¿æåºãå¢å€§ãããã°ãããã213.29ã¯ãè æ©èœãšããŠã®æœ æµãåã³GFRãææã«æ¹è¯ããããšãã§ãããè¡æ¶²å°¿çŽ çªçŽ (BUN)åã³è¡æž ã®ã¯ã¬ã¢ããã³ã»ã¬ãã«ãã72æéåŸã«æž¬å®ãããããŠå³6Bã«ç€ºãããã«ãã§ãã«ããã (Fenoldopam)ãš213.29ãå ±ã«ãBUNåã³ã¯ã¬ã¢ããã³ã»ã¬ãã«ã®æžå°ã«ãããå¹æãåãã§ãã£ãã
è
äžå
š(èè¡æ§è
çã®ã©ããã®ã¢ãã«ã«ãããŠ)ã«çœ¹ã£ãŠããã©ããã«213.29ãæäžããä¿è·å¹æ
è åèãžã®éåæ¢ãã解ããããŠè¬å€ãæäžããŠ24æéåã¯72æéåŸã«ãå®æœäŸïŒã«ãŠäœ¿çšããåç©ããè èãæ¡åãããåæããçµç¹ã«ããå®éšãè¡ãªã£ãã
è åèãžã®éåæ¢ãã解ããããŠè¬å€ãæäžããŠ24æéåã¯72æéåŸã«ãå®æœäŸïŒã«ãŠäœ¿çšããåç©ããè èãæ¡åãããåæããçµç¹ã«ããå®éšãè¡ãªã£ãã
å³ïŒã«ç€ºãããã«ã糞çäœåšèŸºã®èšåŒµã瀺ã糞çäœã®æ°ã¯213.29ã«ããæ²»ççµæãšããŠææã«æžå°ãããåæ§ã«çŽ°èã®å±ãå«ãæ¡å管ã®æ°ã213.29ã«ãã£ãŠææã«æžå°ããããããã®çµæã§ã¯ãè
æ©èœã®æ¹è¯äžŠã³ã«è¶
埮现æ§é äœã®æå·ãšãã®åŸã®èè¡æ§é害ããã®ä¿è·ã«ã213.29ã®äœ¿çšãææããŠããã
äž¡åŽã®è
åèéåæ¢ã(clamping)ã«ããè
äžå
šã«çœ¹ã£ãã©ããã«ã213.29ã1æ¥1åæäžããå¹æã«å¯Ÿãã1æ¥2åæäžããå¹æ
213.29ã®æäžé »åºŠã®å¢å€§ããã©ããRAO-ã¢ãã«ã®è æ©èœã«è¯å¥œãªå¹æãåãŒããã©ããã®æ±ºå®ããããã«ã1mg/kgã®213.29ã1æ¥1åãš1æ¥2åé泚ãããããŠïŒæ¥ç®ãš5æ¥ç®ãšãæ¯èŒãããåŸãããçµæãå³8ã«ç€ºããæ¥ïŒãŸã§ã®ç³žçäœæ¿Ÿéé床(GFR)ãè è¡æŒ¿æµåºŠ(RPF)åã³å°¿ã®æµéç(UV)ãã1æ¥1å(qd)ãš1æ¥2å(bid)ã®æäžã®å ŽååãçšåºŠã«æ¹è¯ããããããããªããããããã®è æ©èœãã©ã¡ãŒã¿ã¯ãè¬å€ã1æ¥1åããããã1æ¥2åæäžãããå Žåã«1æ¥ç®ã«åçãªæ¹è¯ã瀺ãããåŸã£ãŠãè¬å€ã®è¬ç©åæ åŠãšçµã³ã€ããŠ213.29ã®æäžé »åºŠããè æ©èœã®æ©èœäžè¯ãªå Žåã«ãããè æ©èœãæ¹è¯ããããšãã§ããã
213.29ã®æäžé »åºŠã®å¢å€§ããã©ããRAO-ã¢ãã«ã®è æ©èœã«è¯å¥œãªå¹æãåãŒããã©ããã®æ±ºå®ããããã«ã1mg/kgã®213.29ã1æ¥1åãš1æ¥2åé泚ãããããŠïŒæ¥ç®ãš5æ¥ç®ãšãæ¯èŒãããåŸãããçµæãå³8ã«ç€ºããæ¥ïŒãŸã§ã®ç³žçäœæ¿Ÿéé床(GFR)ãè è¡æŒ¿æµåºŠ(RPF)åã³å°¿ã®æµéç(UV)ãã1æ¥1å(qd)ãš1æ¥2å(bid)ã®æäžã®å ŽååãçšåºŠã«æ¹è¯ããããããããªããããããã®è æ©èœãã©ã¡ãŒã¿ã¯ãè¬å€ã1æ¥1åããããã1æ¥2åæäžãããå Žåã«1æ¥ç®ã«åçãªæ¹è¯ã瀺ãããåŸã£ãŠãè¬å€ã®è¬ç©åæ åŠãšçµã³ã€ããŠ213.29ã®æäžé »åºŠããè æ©èœã®æ©èœäžè¯ãªå Žåã«ãããè æ©èœãæ¹è¯ããããšãã§ããã
ã·ã¹ãã©ãã³ã«ããæ¥æ§å°¿çŽ°ç®¡ã®å£æ»ãåã³è
äžå
šãšãªã£ãŠããã©ããã«ããã213.29ã®æäžå¹æ
æ¥æ§å°¿çŽ°ç®¡ã®å£æ»ãåã³è
äžå
šããæŸå°ç·é 圱å€(radiocontrast agent)ãåã¬ã³æ§ååç©ãåã³æäœã䜿çšããçŽæ¥ççµæã§ãããã©ããã®ã·ã¹ãã©ãã³ã«èªçºãããæ¥æ§å°¿çŽ°ç®¡ã®å£æ»ã¢ãã«ããããã®è
äžå
šã®å€ãã®ç¹æ§ãåçããããã«ç€ºããã(Lieberthal,W.,Nigam,S.K.(2000);Am.J Physiol.Renal.Physiol.278(1):F1-F12)ã
ã·ã¹ãã©ãã³ã«ãŠèªçºãããæ¥æ§å°¿çŽ°ç®¡å£æ»ã®ã©ããã®ã¢ãã«
æ¥æ§å°¿çŽ°ç®¡ã®å£æ»ãã1æ¥ç®Sprague-Dawley ãªã¹ã®ã©ããã«17.5mg/kgã®ã·ã¹ãã©ãã³ãæ³šå ¥ããããšã§èªçºãããã5æ¥ç®ãŸã§ãè èæ©èœã®ãã©ã¡ãŒã¿ããªãã¡GFR,RPFåã³UVããç¡èŠãããéãŸã§åçã«æžå°ãã(å³9Aã«ãããSal[çççé£å¡©æ°Žãã«ã©ã )ãããã¯ãã·ã¹ãã©ãã³ã§æ²»çããã©ããã«ãããŠä»¥åŸ50%ã®æ»äº¡çã§ãã£ããè¡æ¶²å°¿çŽ çªçŽ (BUN)åã³ã¯ã¬ã¢ããã³ã®ã¬ãã«ãã5æ¥ç®ãŸã§åçã«å¢å€§ãã(ããŒã¿ãæ瀺ããŠããªã)ã
æ¥æ§å°¿çŽ°ç®¡ã®å£æ»ãã1æ¥ç®Sprague-Dawley ãªã¹ã®ã©ããã«17.5mg/kgã®ã·ã¹ãã©ãã³ãæ³šå ¥ããããšã§èªçºãããã5æ¥ç®ãŸã§ãè èæ©èœã®ãã©ã¡ãŒã¿ããªãã¡GFR,RPFåã³UVããç¡èŠãããéãŸã§åçã«æžå°ãã(å³9Aã«ãããSal[çççé£å¡©æ°Žãã«ã©ã )ãããã¯ãã·ã¹ãã©ãã³ã§æ²»çããã©ããã«ãããŠä»¥åŸ50%ã®æ»äº¡çã§ãã£ããè¡æ¶²å°¿çŽ çªçŽ (BUN)åã³ã¯ã¬ã¢ããã³ã®ã¬ãã«ãã5æ¥ç®ãŸã§åçã«å¢å€§ãã(ããŒã¿ãæ瀺ããŠããªã)ã
ããã«213.29ããããã®çç¶ã«æçã§ãããã©ãããå€å®ããããã«ã1mg/kgã©ããã«é泚åŸ5æ¥ç®ã«ãŠãè
èæ©èœè©Šéšãè¡ãªã£ããå³9Aã«ç€ºãããã«ãGFR,RPFåã³UVããççé£å¡©æ°Žã«ãŠåŠçããã©ãããšæ¯èŒããŠåçã«æ¹è¯ãããååç©ãã5mg/kgã«ãŠ1æ¥ã«3å(tid)äžããããšãã2æ¥ç®ããéå§ããããŠ5æ¥ãŸã§ç¶ç¶ãã(å³9A)ãè¡æ¶²å°¿çŽ çªçŽ ãšã¯ã¬ã¢ããã³ãšã®ã¬ãã«ãå
±ã«äºæããããã«æžå°ããã
è
äžå
šã®2å¹ã®ã©ããã®ã¢ãã«ã«ããåŸãããçµæ(èè¡æ§åã¯è
æ¯æ§ã«ããããã®æ¥æ§è
äžå
šã®éèŠãªç¹æ§ãåçããã¢ãã«ãšããŠæç®[Lieberthal,W.,Nigam,S.K.(2000);Am.J.Physiol.Renal.Physiol.278(1):F1-F12]ã«ãããŠååã«å®èšŒããåãå
¥ãããã)ã«ãã瀺ãããããšã¯ã213.29åã³ãã®èªå°äœãè
æ©èœãæ¹è¯ãããããŠè
é害ã®æªåã«å¯Ÿããä¿è·ãæäŸããããããã£ãŠããããã®ååç©ããæ¥æ§è
äžå
šåã³æ
¢æ§è
äžè¯ãšãªãããã®å Žåã®æ²»çå€ãšããŠäœ¿çšããããšãã§ããã
æ¬çºæã¯ããã®å¥œãŸããå®æœäŸã®æ¹æ³ã«ããæ¬æ现æžã«èšèŒãããŠããããæ·»ä»ãããã¯ã¬ãŒã ã«æèšãããŠããããã«ãæ¬çºæã®ç²Ÿç¥åã³ç¹æ§ããéžè±ããããšãªãããããå€æŽããããšãã§ããã
æ¬çºæãäžè¬çã«èª¬æããããšã§ãæ¬çºæã®å¥œãŸããæ
æ§ãäŸç€ºããããã®æ·»ä»å³é¢ã«ã€ããŠä»¥äžèª¬æããïŒ
Claims (27)
- 以äžã®äžè¬åŒ
âïŒâïŒâïŒâïŒâïŒâïŒâïŒâïŒâ
ïŒããã§ã
ã¯æ°ŽçŽ åååã³ã«ã«ãã¡ãŒãåºåã¯ã¢ã·ã«åºã§ããä¿è·åºãããæã矀ããéžæããïŒ
ã¯ïŒã€åã³ïŒã€ã®ïŒ¬âãªãžã³æ®åºããæã矀ããéžæããïŒ
ïŒã¯ãâïŒïŒïŒïŒïŒâããã§ãã«ã¢ã©ãã³åã³ïŒ€âïŒïŒïŒïŒïŒããã§ãã«ã¢ã©ãã³ããæã矀ããéžæããïŒ
ïŒã¯ïŒŽïœïœã§ããïŒ
ïŒã¯ïŒ³ïœ ïœã§ããïŒ
ïŒã¯ïŒŽïœïœåã³ïŒ°ïœïœ ããæã矀ããéžæããïŒ
ïŒã¯ïŒ§ïœïœåã³ïŒ¡ïœïœããæã矀ããéžæããïŒ
ïŒã¯ïŒ¡ïœïœãïœïœãåã³ïŒ³ïœ ïœããæã矀ããéžæããïŒ
ïŒã¯ïŒ¬ïœ ïœïŒïŒ©ïœïœ ïŒïŒ¶ïœïœåã³äžåšããæã矀ããéžæããïŒ
ïŒã¯ïŒ§ïœïœåã³äžåšããæã矀ããéžæãããïŒãæãããããã¹ã¿ã°ã©ã³ãžã³ïŒ¥ïŒå容äœïŒ¥ïŒ°ïŒã®ããããã¢ã³ã¿ãŽãã¹ãã - ãïŒã€ã®ïŒ¬âãªãžã³æ®åºã§ãããè«æ±é ïŒã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ãã
- ïŒãïœïœã§ãããè«æ±é ïŒåã¯ïŒã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ãã
- ïŒãïœïœã§ãããè«æ±é ïŒãïŒã®ããããïŒé ã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ãã
- ïŒãïŒ¬ïœ ïœåã³äžåšããæã矀ããéžæããããè«æ±é ïŒãïŒã®ããããïŒé ã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ãã
- ãæ°ŽçŽ ã§ãããè«æ±é ïŒãïŒã®ããããïŒé ã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ãã
- ïŒãâïŒïŒïŒïŒïŒããã§ãã«ã¢ã©ãã³ã§ãããè«æ±é ïŒãïŒã®ããããïŒé ã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ãã
- ã¢ã·ã«åºããã·ã¯ãããã·ã«ããã§ãã«ããã³ãžã«ã䞊ã³ã«ïŒãïŒåã«åã¶ççŽ ååã®çãçŽéã¢ã«ãã«åã³åæéã¢ã«ãã«ããæã矀ããéžæãããçæ°Žæ§éšåã§ãããè«æ±é ïŒãïŒã®ããããïŒé ã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ãã
- ã¢ã·ã«åºãã¢ã»ãã«åºã§ãããè«æ±é ïŒã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ãã
- ã¢ã·ã«åºããã³ãŸã€ã«åºã§ãããè«æ±é ïŒã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ãã
- 213.19(bip)tsyealk(é åçªå·2)ïŒ213.20(bip)tsyeglk(é åçªå·3)ïŒ213.21(bip)tsyealKK(é åçªå·4)ïŒ213.22(bip)tsyeglKK(é åçªå·5)ïŒ213.23(bip)tsyeslK(é åçªå·6)ïŒ213.24(bip)tsyeslKK(é åçªå·7)ïŒ213.25(bip)tsyeaK(é åçªå·8)ïŒ213.26(bip)tsyesK(é åçªå·9)ïŒ213.27(Bip)tsyealKK(é åçªå·10)ïŒ213.28(bip)tsyeaLKK(é åçªå·11)ïŒ213.29(Bip)tsyeaLKK(é åçªå·12)ïŒåã³213.30(bip)tsyealGKK(é åçªå·13)ããæã矀ããéžæããã
ããã§ãBipãâïŒïŒïŒïŒïŒããã§ãã«ã¢ã©ãã³ã§ããããããŠbipãâïŒïŒïŒïŒïŒããã§ãã«ã¢ã©ãã³ã§ããããããŠïŒ€âã¢ããé žã¯å°æåã§èå¥ããããããŠïŒ¬âã¢ããé žã¯å€§æåã§èå¥ããããè«æ±é ïŒã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ãã - ããã¹ã¿ã°ã©ã³ãžã³ïŒ¥ïŒå容äœïŒ¥ïŒ°ïŒã®çç©æŽ»æ§ãé»å®³ããããšãã§ãããè«æ±é ïŒãïŒïŒã®ããããïŒé ã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ãã
- ããã¹ã¿ã°ã©ã³ãžã³ïŒ¥ïŒå容äœïŒ¥ïŒ°ïŒã®çç©æŽ»æ§ãé»å®³ããããšãã§ãããè«æ±é ïŒïŒã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ãã®ããããæš¡å£ç©ã
- è«æ±é ïŒïŒã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ããçŽïŒïŒïŒãçŽïŒïŒïŒïœïœå«ãã§æãå»è¬çµæç©ã
- è«æ±é ïŒïŒã«èšèŒã®ããããæš¡å£ç©ãçŽïŒïŒïŒãçŽïŒïŒïŒïœïœå«ãã§æãå»è¬çµæç©ã
- æ«æã®è çŸæ£ãåŠçœ®ããæ¹æ³ã§ãã£ãŠãæ²»ççã«æå¹éã®è«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ãå¿ èŠãšãããæ£è ã«å¯Ÿãæäžããããšãå«ãã§æãæ¹æ³ã
- æ¥æ§è äžå šãåŠçœ®ããæ¹æ³ã§ãã£ãŠãæ²»ççã«æå¹éã®è«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ãå¿ èŠãšãããæ£è ã«å¯Ÿãæäžããããšãå«ãã§æãæ¹æ³ã
- è æ©èœé害ãåŠçœ®ããæ¹æ³ã§ãã£ãŠãæ²»ççã«æå¹éã®è«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ãå¿ èŠãšãããæ£è ã«å¯Ÿãæäžããããšãå«ãã§æãæ¹æ³ã
- 糞çäœæ¿Ÿéãåäžãããããã®æ¹æ³ã§ãã£ãŠãæ²»ççã«æå¹éã®è«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ãå¿ èŠãšãããæ£è ã«å¯Ÿãæäžããããšãå«ãã§æãæ¹æ³ã
- å°¿æåºéãåäžããããè«æ±é ïŒïŒã«èšèŒã®æ¹æ³ã
- åè管éåçãåŠçœ®ããããã®æ¹æ³ã§ãã£ãŠãæ²»ççã«æå¹éã®è«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ãå¿ èŠãšãããæ£è ã«å¯Ÿãæäžããããšãå«ãã§æãæ¹æ³ã
- åè管ãéãããè«æ±é ïŒïŒã«èšèŒã®æ¹æ³ã
- ã¢ãã»ã€ã«ãããŠè«æ±é ïŒïŒã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ãã䜿çšããæ¹æ³ã§ãã£ãŠïŒ
ïœïŒå€©ç¶ã«åã¯çµæãçã«ããã¹ã¿ã°ã©ã³ãžã³ïŒ¥ïŒå容äœïŒ¥ïŒ°ïŒãçºçŸããŠãã现èåã¯çµç¹ãå¹é€ããã¹ãããïŒ
ïœïŒåèšå¹é€çŽ°èåã¯çµç¹ããäžå®éã®è«æ±é ïŒïŒã«èšèŒã®ããããã¢ã³ã¿ãŽãã¹ããçšããŠãæ¢ç¥ã®æ¿åºŠã®åèšå容äœã®ã¢ãŽãã¹ãã®ååšäžåã¯äžåšäžã§åŠçœ®ããã¹ãããïŒ
ïœïŒïŒ§Î±ã¿ã³ãã¯è³ªã«ããçµååã³å æ°Žå解ãç°ç¶ã¢ããã·ã³äžãªã³é žã®åæã现èã«ã«ã·ãŠã ã®å€åã现èå¢æ®äžŠã³ã«ïŒãããã¯ååãéºäŒåçºçŸã®å€ååã³å¹³æ»çåçž®åã¯æ¡åŒµããæã矀ããéžæããããåèšå容äœã®çç©æŽ»æ§ã®ïŒåã¯è€æ°ã®èŠ³ç¹ã枬å®ããã¹ãããã
ãå«ãã§æãæ¹æ³ã - ã¢ãã»ã€ã«ãããŠè«æ±é ïŒïŒã«èšèŒã®ããããæš¡å£ç©ã䜿çšããæ¹æ³ã§ãã£ãŠïŒ
ïœïŒå€©ç¶ã«åã¯çµæãçã«ããã¹ã¿ã°ã©ã³ãžã³ïŒ¥ïŒå容äœïŒ¥ïŒ°ïŒãçºçŸããŠãã现èåã¯çµç¹ãå¹é€ããã¹ãããïŒ
ïœïŒåèšå¹é€çŽ°èåã¯çµç¹ããäžå®éã®è«æ±é ïŒïŒã«èšèŒã®ããããæš¡å£ç©ãçšããŠãæ¢ç¥ã®æ¿åºŠã®åèšå容äœã®ã¢ãŽãã¹ãã®ååšäžåã¯äžåšäžã§åŠçœ®ããã¹ãããïŒ
ïœïŒïŒ§Î±ã¿ã³ãã¯è³ªã«ããçµååã³å æ°Žå解ãç°ç¶ã¢ããã·ã³äžãªã³é žã®åæã现èã«ã«ã·ãŠã ã®å€åã现èå¢æ®äžŠã³ã«ïŒãããã¯ååãéºäŒåçºçŸã®å€ååã³å¹³æ»çåçž®åã¯æ¡åŒµããæã矀ããéžæããããåèšå容äœã®çç©æŽ»æ§ã®ïŒåã¯è€æ°ã®èŠ³ç¹ã枬å®ããã¹ãããã
ãå«ãã§æãæ¹æ³ã - ããã¹ã¿ã°ã©ã³ãžã³ïŒ¥ïŒå容äœïŒ¥ïŒ°ïŒã®çç©æŽ»æ§ãã¢ãã»ã€ããããã®åæ¥çšãããã§ãã£ãŠãæŸå°æ§åäœäœãããªãã³ãåã¯é µçŽ ããæã矀ããéžæãããããŒã«ãŒã§æšèãããŠããè«æ±é ïŒïŒã«èšèŒã®ãããããå«ãã§æããããã
- ããã¹ã¿ã°ã©ã³ãžã³ïŒ¥ïŒå容äœïŒ¥ïŒ°ïŒã®çç©æŽ»æ§ãã¢ãã»ã€ããããã®åæ¥çšãããã§ãã£ãŠãæŸå°æ§åäœäœãããªãã³åã³é µçŽ ããæã矀ããéžæãããããŒã«ãŒã§æšèãããŠããè«æ±é ïŒïŒã«èšèŒã®ããããæš¡å£ç©ãå«ãã§æããããã
- ããã¹ã¿ã°ã©ã³ãžã³ïŒ¥ïŒå容äœïŒ¥ïŒ°ïŒã®çç©æŽ»æ§ãã¢ãã»ã€ããããã®åæ¥çšãããã§ãã£ãŠãæŸå°æ§åäœäœãããªãã³ãåã¯é µçŽ ããæã矀ããéžæãããããŒã«ãŒã§æšèãããŠããè«æ±é ïŒïŒã«èšèŒã®ãããããå«ãã§æããããã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38233602P | 2002-05-23 | 2002-05-23 | |
| PCT/CA2003/000771 WO2003099857A1 (en) | 2002-05-23 | 2003-05-23 | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006506327A JP2006506327A (ja) | 2006-02-23 |
| JP2006506327A5 true JP2006506327A5 (ja) | 2006-09-14 |
Family
ID=29584392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004508111A Pending JP2006506327A (ja) | 2002-05-23 | 2003-05-23 | ããã¹ã¿ã°ã©ã³ãžã³ïœ ïŒã®å容äœãµãã¿ã€ãïœ ïœïŒã®ã¢ã³ã¿ãŽãã¹ãã»ããªãããã |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040023853A1 (ja) |
| EP (1) | EP1506220A1 (ja) |
| JP (1) | JP2006506327A (ja) |
| CN (1) | CN1662551A (ja) |
| AU (1) | AU2003233297A1 (ja) |
| BR (1) | BR0311247A (ja) |
| CA (1) | CA2485485A1 (ja) |
| WO (1) | WO2003099857A1 (ja) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1742662A2 (en) * | 2004-05-03 | 2007-01-17 | Astellas Pharma Inc. | Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases |
| US20060115785A1 (en) | 2004-11-30 | 2006-06-01 | Chunhua Li | Systems and methods for intra-oral drug delivery |
| WO2007146187A2 (en) * | 2006-06-06 | 2007-12-21 | Reika Ortho Technologies, Inc. | Transduction orthodontic devices |
| CN101041687B (zh) * | 2007-02-28 | 2010-09-29 | é¿æ¥åæ³°å»è¯çç©ææ¯æéèŽ£ä»»å ¬åž | Pge2ç¹åŒç»åçå¬èäœç¯äžèœåçéæ¹æ³ååæèœççšé |
| JPWO2010087425A1 (ja) | 2009-01-30 | 2012-08-02 | åœç«å€§åŠæ³äººäº¬éœå€§åŠ | åç«è ºçã®é²è¡æå¶å€ããã³é²è¡æå¶æ¹æ³ |
| NZ609887A (en) | 2010-09-29 | 2015-01-30 | Nb Health Lab Co Ltd | Antibody against human prostaglandin e2 receptor ep4 |
| MY168609A (en) | 2013-06-12 | 2018-11-14 | Kaken Pharma Co Ltd | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient |
| TW201623277A (zh) * | 2014-03-26 | 2016-07-01 | å®æ¯æ³°äŸè£œè¥è¡ä»œæéå ¬åž | é¯èºååç© |
| US10279044B2 (en) | 2015-05-29 | 2019-05-07 | Purdue Research Foundation | Bone fracture repair by targeting of agents that promote bone healing |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituÃdos como moduladores de los receptores de pge2 |
| EP3625224B1 (en) | 2017-05-18 | 2021-08-04 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| US11839613B2 (en) | 2017-05-18 | 2023-12-12 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| AU2018269666B2 (en) | 2017-05-18 | 2022-02-03 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as PGE2 receptor modulators |
| KR102612649B1 (ko) | 2017-05-18 | 2023-12-11 | ìŽë륎ìì íë§ìí°ì»¬ì€ 늬믞í°ë | Pge2 ìì©ì²Ž ì¡°ì ì ë¡ìì 벀조ížë ë° ë²€ì¡°í°ì€íë Œ ì ë첎 |
| CA3063788A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| KR20230107228A (ko) | 2020-11-13 | 2023-07-14 | ì€ë ž ìŒêŸží ê³ êµ ê°ë¶ìí€ê°ìŽì€ | Ep4 êžžíìœê³Œ ë©Žì 첎í¬í¬ìžíž ì íŽ ë¬Œì§ì ë³ì©ì ìí ì ì¹ë£ |
| WO2024111404A1 (ja) * | 2022-11-21 | 2024-05-30 | ååçºé µãã€ãªæ ªåŒäŒç€Ÿ | æããå€ã«ããèªçºãããæ¥æ§è é害ã®äºé²åã¯æ²»çå€ |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605814A (en) * | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
| TWI247606B (en) * | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
| DE60020997T2 (de) * | 1999-12-06 | 2006-05-24 | Hopital Sainte-Justine, Montreal | Verbindungen zur Behandlung von abnormaler Glomerulusfiltration, Ductus arteriosus apertus und Osteoporose |
-
2003
- 2003-05-23 AU AU2003233297A patent/AU2003233297A1/en not_active Abandoned
- 2003-05-23 CN CN038146851A patent/CN1662551A/zh active Pending
- 2003-05-23 BR BR0311247-0A patent/BR0311247A/pt not_active IP Right Cessation
- 2003-05-23 JP JP2004508111A patent/JP2006506327A/ja active Pending
- 2003-05-23 WO PCT/CA2003/000771 patent/WO2003099857A1/en not_active Application Discontinuation
- 2003-05-23 US US10/444,516 patent/US20040023853A1/en not_active Abandoned
- 2003-05-23 EP EP03727063A patent/EP1506220A1/en not_active Withdrawn
- 2003-05-23 CA CA002485485A patent/CA2485485A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006506327A5 (ja) | ||
| JP2006506327A (ja) | ããã¹ã¿ã°ã©ã³ãžã³ïœ ïŒã®å容äœãµãã¿ã€ãïœ ïœïŒã®ã¢ã³ã¿ãŽãã¹ãã»ããªãããã | |
| KR20230036156A (ko) | α4β7 ìží 귞늰 í°ì€ìí 륎 í©í°ë êžžíì | |
| US20160237119A1 (en) | C-Met Protein Agonist | |
| JP2014111637A (ja) | ã¡ã©ãã³ã«ãã³å容äœç¹ç°çãããã | |
| JP6934011B2 (ja) | ïœïœïœïœïœïœïœïœïœïœïœïœïœ ïŒçµåãããã | |
| JP2004537581A (ja) | ã¡ã©ãã³æ¿çž®ãã«ã¢ã³æ®æç©è³ª | |
| Novoa et al. | Variation of the net charge, lipophilicity, and side chain flexibility in Dmt1-DALDA: effect on opioid activity and biodistribution | |
| JP6633523B2 (ja) | ïœïœâïŒïŒã®äºéäœé»å®³å€èèªé žèªå°äœ | |
| US20230287051A1 (en) | Inhibitors of complement factor c3 and their medical uses | |
| EP1244693B1 (en) | Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis | |
| US7479480B2 (en) | Peptides that promote lipid efflux | |
| JPH09503906A (ja) | çµæãïœïŒïŒïŒå容äœãªãã³ã«ãã®ã¢ãŽãã¹ãããã³ã¢ã³ã¿ãŽãã¹ã | |
| US20080199398A1 (en) | Novel Peptides That Promote Lipid Efflux | |
| US7414029B2 (en) | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 | |
| JP2021523931A (ja) | ã¡ã©ãã³ã«ãã³å容äœç¹ç°çãããã補å€åã³æ¶å管ç¹ç°çééæ¹æ³ | |
| JP2003522184A (ja) | ã¡ã©ãã³æ¿çž®ãã«ã¢ã³é¡äŒŒäœ | |
| EP1878741A2 (en) | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 | |
| WO2017073764A1 (ja) | æ°èŠïœïœïŒå容äœã¢ãŽãã¹ã | |
| US10092620B2 (en) | Uses of cyclic peptides for treating and preventing atherosclerosis | |
| WO2015083816A1 (ja) | æ°èŠïœïœïŒå容äœã¢ãŽãã¹ã | |
| US20030105278A1 (en) | Melanin-concentrating hormone analogs | |
| WO2024168055A1 (en) | Tnf-alpha binding agents and methods of using the same | |
| US20040147432A1 (en) | Melanin-concentrating hormone analogs | |
| CN115484971A (zh) | é¶åèçœçåå |